Biochemical and Immunological Studies on Poly L-Tyrosine Exposed to Active Nitrogen Intermediates by Khan, Fozia

Ji(BS'I^CT 
Reactive nitrogen and oxygen species are a ubiquitous part of human life having 
both beneficial and harmftjl effects. These are produced in cells under physiological 
conditions during oxygen metabolism and other redox processes that are of vital 
importance for the biological function. However, excess of these radicals react with 
cellular lipids, proteins and nucleic acids leading to local injury and eventual organ 
dysfunction. Oxidative stress has a probable role in the pathogenesis of a variety of 
human diseases. 
Nitric oxide, a multi-faceted bioregulatory agent produced by many types of cells, 
is known to play a critical role in both regulatory processes and cell defense, yet it also 
participates in collateral reactions, leading to DNA damage and cell death in both nitric 
oxide generating and neighboring cells. Nitric oxide is an important mediator of the 
inflammatory response. It is a strong proinflammatory substance that may increase 
vascular permeability in inflamed tissues. There is extensive suggestive evidence that 
nitric oxide can participate as mediator of tissue damage in autoimmune diseases. 
Reactive nitrogen and oxygen species are implicated in many disease conditions 
including chronic inflammation, arteriosclerosis, rheumatoid arthritis, some 
neurodegenerative diseases, systemic lupus erythematosus and respiratory conditions. 
The increased levels of nitrotyrosine, which have been detected in the tissues affected by 
these diseases, have been attributed to a higher formation of nitric oxide. Therefore, 
nitrotyrosine was proposed as a suitable chemical marker for assessing the nitration level 
in proteins, and it is generally believed that peroxynitrite is the main contributor to the 
formation of nitrotyrosine. However, it has been suggested that nitrotyrosine formation 
may be induced by other species such as nitrogen dioxide, nitrous acid or nitronium 
chloride. Nitration of tyrosine residues of proteins occurs, either on albumin or on 
lipoproteins. Nitric oxide may also interact with nucleic acids, causing DNA strand 
breakage, and react with guanine residues with the formation of 8-nitroguanine, thus 
contributing to a number of diseases. 
Systemic lupus erythematosus is an autoimmune disease with a complex etiology 
and pathogenesis. It is a multisystem chronic, autoimmune disease encompassing a 
spectrum of diseases defined by clinical criteria. Both cell mediated and humoral 
autoreactivity precipitates SLE. One of the characteristics of SLE is a long-term high 
affinity immune response to self-antigens. SLE is associated with the presence of 
autoantibodies against tissue and cellular components such as DNA, RNA, cytoplasmic 
elements found in serum, phospholipids, ribonucleoproteins and histones. However, the 
main autoantibodies found in SLE are antinuclear autoantibodies that react with nuclear 
antigens such as dsDNA, ssDNA, chromatin and histones. However, antibodies not only 
recognize nucleic acid antigens but also react with a number of cellular proteins. 
In the present study, the possible role of native and nitrated poly L-tyrosine in 
SLE was probed. Aqueous solution of poly L-tyrosine (pH 11) was exposed to nitric 
oxide generated by sodium nitrite in acidic medium. The generation of nitric oxide was 
confirmed using carboxy-PTIO, a quencher of nitric oxide radical. The nitric oxide 
induced modifications in poly L-tyrosine were analyzed by UV, fluorescence and circular 
dichroism spectroscopy. 
The UV absorption spectra of nitrated poly L-tyrosine showed a peak shift of 4 nm 
towards shorter wavelength and hypochromicity at 280 nm as compared to native poly L-
tyrosine. Another peak was observed at wavelength of 420 nm, which is characteristic of 
3-nitrotyrosine at pH >9. The data reflects NO induced damage of the aromatic ring of 
tyrosine, as well as nitration of tyrosine forming 3-nitrotyrosine. Damage of the 
chromophoric group was further confirmed by fluorescence spectra and quantitation of 
tyrosine by Lowry's method. 
Formation of low molecular weight species, aggregation, peptide bond cleavage 
was further ascertained by DNA adduct formation, thermal denaturation studies, alkaline 
agarose gel electrophoresis and gel filtration. 
The antigenicity of native and nitrated poly L-tyrosine was probed by inducing 
antibodies in rabbits. The repertoires of specificities of induced antibodies were evaluated 
by direct binding and competition ELISA. The induced antibodies against native and 
nitrated poly L-tyrosine exhibited polyspecificity, a property commonly associated with 
SLE anti-DNA autoantibodies. Anti-native and anti-nitrated poly L-tyrosine antibodies 
showed preferential recognition of respective immunogens in competitive inhibition 
assay as well as dot blot assay. The level of 3-nitrotyrosine was evaluated in the immune 
sera by HPLC. 
A group of SLE sera with high antibody litre were investigated for their specificity 
towards native and nitrated poly L-tyrosine by ELISA. Direct binding ELISA showed 
preferential binding of SLE autoantibodies to nitrated poly L-tyrosine in comparison to 
native poly L-tyrosine and nDNA. Inhibition ELISA reiterated the direct binding results. 
Gel retardation assay further substantiated the binding of native and nitrated poly L-
tyrosine with IgG isolated from SLE sera. The formation of immune complex between 
SLE IgG and native/nitrated antigens confirmed enhanced recognition of nitrated form 
over native poly L-tyrosine by circulating autoantibodies in SLE. 
SLE sera were analyzed for the presence of 3-nitrotyrosine by Western blot 
analysis. The separation and measurement of 3-nitrotyrosine concentration in SLE sera 
was carried out by HPLC indicating that serum 3-nitrotyrosine level is elevated among 
patients with SLE. 
In conclusion, the nitric oxide radical causes nitration as well as structural alteration 
and renders the nitrated form of poly L-tyrosine highly immunogenic. The induced 
antibodies against nitrated poly L-tyrosine showed polyspecificity towards various 
polymers, resembling the antigen binding characteristics of SLE anti-DNA 
autoantibodies. The possibility of nitrated poly L-tyrosine in the production of SLE 
autoantibodies has been probed in the present study. 
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Reactive nitrogen and oxygen species are a ubiquitous part of human life having 
both beneficial and harmful effects. These are produced in cells under physiological 
conditions during oxygen metabolism and other redox processes that are of vital 
importance for the biological function. However, excess of these radicals react with 
cellular lipids, proteins and nucleic acids leading to local injury and eventual organ 
dysfunction. Oxidative stress has a probable role in the pathogenesis of a variety of 
human diseases. 
Nitric oxide, a multi-faceted bioregulatory agent produced by many types of cells, 
is known to play a critical role in both regulatory processes and cell defense, yet it also 
participates in collateral reactions, leading to DNA damage and cell death in both nitric 
oxide generating and neighboring cells. Nitric oxide is an important mediator of the 
inflammatory response. It is a strong proinflammatory substance that may increase 
vascular permeability in inflamed tissues. There is extensive suggestive evidence that 
nitric oxide can participate as mediator of tissue damage in autoimmune diseases. 
Reactive nitrogen and oxygen species are implicated in many disease conditions 
including chronic inflammation, arteriosclerosis, rheumatoid arthritis, some 
neurodegenerative diseases, systemic lupus erythematosus and respiratory conditions. 
The increased levels of nitrotyrosine, which have been detected in the tissues affected by 
these diseases, have been attributed to a higher formation of nitric oxide. Therefore, 
nitrotyrosine was proposed as a suitable chemical marker for assessing the nitration level 
in proteins, and it is generally believed that peroxynitrite is the main contributor to the 
formation of nitrotyrosine. However, it has been suggested that nitrotyrosine formation 
may be induced by other species such as nitrogen dioxide, nitrous acid or nitronium 
chloride. Nitration of tyrosine residues of proteins occurs, either on albumin or on 
lipoproteins. Nitric oxide may also interact with nucleic acids, causing DNA strand 
breakage, and react with guanine residues with the formation of 8-nitroguanine, thus 
contributing to a number of diseases. 
Systemic lupus erythematosus is an autoimmune disease with a complex etiology 
and pathogenesis. It is a multisystem chronic, autoimmune disease encompassing a 
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spectrum of diseases defined by clinical criteria. Both cell mediated and humoral 
autoreactivity precipitates SLE. One of the characteristics of SLE is a long-term high 
affinity immune response to self-antigens. SLE is associated with the presence of 
autoantibodies against tissues and cellular components such as DNA, RNA, cytoplasmic 
elements found in serum, phospholipids, ribonucleoproteins and histones. However, the 
main autoantibodies found in SLE are antinuclear autoantibodies that react with nuclear 
antigens such as dsDNA, ssDNA, chromatin and histones. However, antibodies not only 
recognize nucleic acid antigens but also react with a number of cellular proteins. 
In the present study, the possible role of native and nitrated poly L-tyrosine in 
SLE has been probed. Aqueous solution of poly L-tyrosine (pH 11) was exposed to nitric 
oxide generated by sodium nitrite in acidic medium. The generation of nitric oxide was 
confirmed using carboxy-PTIO, a quencher of nitric oxide radical. The nitric oxide 
induced modifications in poly L-tyrosine were analyzed by UV, fluorescence and circular 
dichroism spectroscopy. 
The UV absorption spectra of nitrated poly L-tyrosine showed a peak shift of 4 nm 
towards shorter wavelength and hypochromicity at 280 nm as compared to native poly L-
tyrosine. Another peak was observed at wavelength of 420 nm, which is characteristic of 
3-nitrotyrosine at pH >9. The data reflects NO induced damage of the aromatic ring of 
tyrosine, as well as nitration of tyrosine forming 3-nitrotyrosine. Damage of the 
chromophoric group was further confirmed by fluorescence spectra and quantitation of 
tyrosine by Lowry's method. 
Formation of low molecular weight species, aggregation, peptide bond cleavage 
was further ascertained by DNA adduct formation, thermal denaturation studies, alkaline 
agarose gel electrophoresis and gel filtration. 
The antigenicity of native and nitrated poly L-tyrosine was probed by inducing 
antibodies in rabbits. The repertoires of specificities of induced antibodies were evaluated 
by direct binding and competition ELISA. The induced antibodies against native and 
nitrated poly L-tyrosine exhibited polyspecificity, a property commonly associated with 
SLE anti-DNA autoantibodies. Anti-native and anti-nitrated poly L-tyrosine antibodies 
showed preferential recognition of respective immunogens in competitive inhibition 
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assay as well as dot blot assay. The level of 3-nitrotyrosine was evaluated in the immune 
sera by HPLC. 
A group of SLE sera with high antibody titre were investigated for their specificity 
towards native and nitrated poly L-tyrosine by ELISA. Direct binding ELISA showed 
preferential binding of SLE autoantibodies to nitrated poly L-tyrosine in comparison to 
native poly L-tyrosine and nDNA. Inhibition ELISA reiterated the direct binding results. 
Gel retardation assay further substantiated the binding of native and nitrated poly L-
tyrosine with IgG isolated from SLE sera. The formation of immune complex between 
SLE IgG and native/nitrated antigens confirmed enhanced recognition of nitrated form 
over native poly L-tyrosine by circulating autoantibodies in SLE. 
SLE sera were analyzed for the presence of 3-nitrotyrosine by Western blot 
analysis. The separation and measurement of 3-nitrotyrosine concentration in SLE sera 
was caiTied out by HPLC indicating that serum 3-nitrotyrosine level is elevated among 
patients with SLE. 
In conclusion, the nitric oxide radical causes nitration as well as structural alteration 
and renders the nitrated form of poly L-tyrosine highly immunogenic. The induced 
antibodies against nitrated poly L-tyrosine showed polyspecificity towards various 
polymers, resembling the antigen binding characteristics of SLE anti-DNA 
autoantibodies. The possibility of nitrated poly L-tyrosine in the production of SLE 
autoantibodies has been probed in the present study. 
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Tyrosine is an aromatic amino acid, containing a plienyl ring attached to a 
methylene (-CH2-) group (Fig. 1). The aromatic ring contains a hydroxy! group, 
which makes tyrosine less hydrophobic and more reactive than other amino 
acids. It is a non-essential amino acid, which is produced in cells by 
hydroxylating the essential amino acid, phenylalanine. Half of phenylalanine 
required by the body goes into the production of tyrosine, if the diet is rich 
in tyrosine itself, then the requirement for phenylalanine is reduced by 
about 50%. Phenylalanine hydroxylase is a mixed-function oxygenase: one atom 
of oxygen is incorporated into water and the other into the hydroxyl group 
of tyrosine. The reductant is the tetrahydrofolate related cofactor tetrahydrobiopterin, 
which is maintained in the reduced state by the NADH-dependent enzyme 
dihydropteridine reductase (Fig. 2). 
Tyrosine is a neutral, genetically coded amino acid and is important to the 
structure of almost all proteins in the body. It is also a precursor of several 
neurotransmitters like dopa, dopamine, norepinephrine and epinephrine. Through its 
effect on neurotransmitters, it may affect several health conditions including Parkinson's 
disease, depression and other disorders. Because of its role as a precursor of 
norepinephrine and epinephrine (two of body's main stress related hormones), it 
may also ease the adverse effects of environmental, psychosocial and physical 
stress. Thyroid hormones, which have a role in almost every process in the body, 
also contain tyrosine as part of their stmcture. Tyrosine also aids in the function of 
the adrenal and pituitary glands. Because tyrosine binds unstable molecules (called 
free radicals) that can potentially cause damage to the cells and tissues, it is 
considered a mild antioxidant. Thus, tyrosine may be useful for people who have 
been exposed to harmful chemicals (such as from smoking) and radiation. 
Fig. 1. 3-D Structure of tyrosine 
Y VCH2-CH . 
^=^ NH3 
Phenyalanine ^ 
Phenylalanine 
hydroxylase 
e 
.^_^ COO 
•* HO-f VcH2-CH 
Tyrosine 
« 
H 
NH2. / N ^ ^N. 
N, ^ 
^ i -^CH-CH-CHs 
OH H OH OH 
Hj-biopterin 
NH2. ^N Y 
N 
0 
NAD 
Dihydropteridine 
reductase 
H 
I 
N 
Ik 
M^ CH-CH-CH3 
OH OH 
H2-biopterln 
NADH + H 
Fig. 2. Biosynthesis of tyrosine from phenylalanine 
Poly L-Tyrosine 
Poly L-tyrosine is a homopolymer of L-tyrosine, i.e., many tyrosine residues joined 
by peptide bonds to form a polypeptide chain, which is unbranched. The mean molecular 
weight of an amino acid is 110 Dalton, and so the molecular weights of most 
polypeptides chains are between 5500 and 220,000 Daltons. The polymer of tyrosine is 
found to precipitate out of solution at pH 10.3. Fasman et al. (1964) reported that the 
apparent pKa of poly L-tyrosine in 0.2 M NaCl solution is approximately 11.5. Poly L-
tyrosine has been the object of several studies due to its conformational dependence on 
the properties of various media. In particular, it has been found that poly L-tyrosine 
undergoes a solvent induced structural transition in going from one solution to another 
(Yasui and Keiderling, 1986). For this reason, the establishment of the conformation in 
which aromatic poly amino acids exist in solution is difficult. This explains the various 
structure proposals in the case of Poly L-tyrosine (Beychok and Fasman, 1964; Fasman et 
al., 1964; Applequist and Mehr, 1966; Patrone et al, 1970; Quadrifoglio et al, 1970; 
Jurgen, 1971). For example, poly L-tyrosine can exist in either a helical or a random-
chain conformation in the un-ionized form. The optical rotatory dispersion (ORD) of 
helical poly L-tyrosine (in 0.2 M NaCl, pH 11.2) has been recorded suggesting that 
tyrosyl-tyrosyl interactions occur in the helical conformation and poly L-tyrosine is a 
right-handed helix (Fasman et al, 1964), whereas it has previously been shown that poly 
L-tyrosine forms an intramolecular antiparallel P-structure in aqueous solution (Auer and 
Miller-Auer, 1986). 
There is a correlation between the size of a macromolecule and its immunogenecity. 
The best immunogens tend to have a molecular mass approaching 10 kDa. Generally, 
substances with a molecular mass of less than 5-10 kDa are poor immunogens. Size is not 
by itself sufficient to make a molecule immunogenic, other properties are needed. 
Synthetic homopolymers tend to lack immunogenicity regardless of their size whereas for 
a synthetic copolymer e.g. of glutamic acid and lysine, requires a minimum molecular 
weight of 30-40 kDa. The addition of tyrosine to the copolymer reduces the required 
minimum molecular weight to 10-20 kDa. The addition of aromatic amino acids 
profoundly enhances the immunogenicity of these synthetic polymers. All four levels of 
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protein organization- primary, secondary, tertiary and quaternary contribute to the 
structural complexity of a protein and hence affect its immunogenecity (Goldsby et al., 
2000, Kuby). 
Free Radicals 
A free radical may be defined as any chemical species that contain one or more 
unpaired electrons in the outer shell of the molecule. They are extremely reactive and 
have a very short half life. They quickly react with other compounds, trying to capture 
the needed electron to gain stability. When the attacked molecule loses its electron, it 
becomes a free radical itself, beginning a chain reaction. Once the process is started it can 
cascade, finally resulting in the disruption of a living cell (Freeman, 1984; Halliwell and 
Gutterridge, 1984; Cadenas, 1989). Free radicals can be generated both in vivo and in 
vitro by one of the following mechanisms: 
1. By the hemolytic cleavage of a covalent bond of a molecule, with each fragment 
having an unpaired electron (Von Sonntag, 1987). 
2. By the loss of a single electron from a molecule. 
3. By the addition of a single electron to a molecule. 
The latter, electron transfer, is a more common process in biological synthesis than 
hemolytic fission, which generally requires high energy input from either high 
temperature, UV light or ionizing radiations. Free radicals can be negatively charged, 
positively charged or electrically neutral (Cheeseman and Slater, 1993). The most 
important free radicals in the body are derivatives of oxygen, commonly known as 
reactive oxygen species (ROS) and derivatives of nitrogen known as reactive nitrogen 
species (RNS) (Table 1). 
In living cells, free radicals are produced continuously as by products during normal 
aerobic metabolism (Halliwell and Amoma, 1991) or deliberately as in phogocytosis 
(Cheeseman and Slater, 1993) as well as in pathologic conditions such as tissue 
ischaemia, cancer, inflammation and degenerative diseases (Halliwell and Gutterridge, 
1984). However, environmental factors such as pollution, radiation, cigarette smoke and 
herbicides can also spawn free radicals. Table 2 lists some of the sources of oxidative 
stress. 
TABLE 1 
Examples of ROS and RNS 
REACTIVE OXYGEN SPECES 
1. O2 in its triplet state (''O2) or 
singlet O2 ('O2) 
2. Superoxide anion (O2' ) 
3. Hydroxyl radical ("OH) 
4. Hydrogen peroxide (H2O2) 
5. Hypochlorous acid (HOCl) 
6. Alkoxyl radical (LO') 
REACTIVE NITROGEN SPECIES 
1. Nitric oxide (NO') 
2. Peroxynitrite (ONOO") 
3. Nitrate (NOs') 
4. Nitrite (N02') 
5. Nitrogen dioxide (NO2 ) 
6. Nitrous oxide (N2O4, N2O, N2O3) 
TABLE 2 
Source of Free Radicals in the Body 
Source 
1. Mitochondrial electron transport 
2. Transition metal ions 
3. Inflammation 
4. Enzymes e.g. xanthine oxidase 
5. Drug metabolism 
6. Cigarette smoke 
7. Radiation 
Mechanism 
1. Leakage of superoxide due to inefficient 
reduction of O2 
2. Copper and iron facilitate hydroxyl radical 
formation 
3. Free radicals released by activated 
phagocytes 
4. Release superoxide during reperfusion of 
ischemic tissue 
5. Free radical intermediate created during 
metabolism 
6. Gas phase rich in free radicals 
7. X ray, UV light 
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Reactive Nitrogen Species 
More recently, the role of reactive nitrogen species, such as nitric oxide and its by-
products such as peroxynitrite (0N00~), nitrate (N03~) and nitrite (NOa") have been 
shown to directly affect cellular signaling, vasodilation and immune response (Drew and 
Leeuwenburg, 2002). 
Nitric oxide - A Biological Messenger 
Since its publicized discovery in 1987, nitric oxide has become the focus of major 
research on its control of many cellular fiinctions, including circulation of the blood, 
regulating activities in the brain, lungs, liver, kidneys, stomach, gut, genitals and other 
organs. The 1998 Nobel Prize in physiology or medicine recognized the biological 
significance of nitric oxide (Morgan, 2000). 
Nitric oxide is an uncharged molecule with an unpaired electron. These 
characteristics of nitric oxide make it an ideal messenger molecule. Uncharged NO can 
diffuse freely across membranes. With an unpaired electron, it is called a radical 
molecule, which is highly reactive having a half life of 2-30 seconds and after 
transmitting a signal, it spontaneously decays into nitrite (Lowenstein and Snyder, 1994). 
NO is considered to be an ubiquitous endogenous system which takes part in body's 
homeostatic regulations and in pathological events. Nitric oxide is formed by nitric oxide 
synthase (NOS) in an unusual reaction that converts arginine and oxygen into citrulline 
and nitric oxide (White and Marietta, 1992; McMillan et al., 1992; Mariotto et ai, 2004). 
Three enzyme isoforms produce nitric oxide (Forstermann et ai, 1990; Domenico, 2004): 
a neuronal nitric oxide synthase (NOS 1) and endothelial NOS (NOS 2 and NOS 3) 
(Fig. 3). The inducible form (NOS 2) is found in many cell types, including mononuclear 
phagocytes, hepatocytes and chondrocytes (Bredt et al., 1991a; Marsden et al., 1992). 
The constitutive isoforms (NOS 1 and NOS 3) release small amounts of nitric oxide for a 
brief period to signal adjacent cells, whereas the inducible isoform releases large amounts 
of nitric oxide continuously to eliminate bacteria and parasites. Nitric oxide diffuses out 
of the cell that generates it and into target cells, where it interacts with specific 
molecular targets (Table 3). 
L-arginine + 2 NADPH + 0 2 •L-citrulline + NO + 2NADP+ 
L-Arginine L-CitruUine 
NH2-C(NH2)-NH-(CH2) 3 -CH(NH2) -COOH H2N-CONH-CH2-CH2-CH2-CH(NH2)-COOH 
NADPH -> NADP^ 
2+ Cofactors for NOS: Calmodulin / Ca , Haem, FMN, FAD 
o. NO 
Fig. 3. The production of NO and L-citrulline from L-arginine, O2, and NADPH-derived 
electrons. 
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TABLE 3 
Molecular Targets of Nitric Oxide 
Nitric oxide target 
molecules 
Proteins 
Nucleic acids 
NO radical molecule 
Mechanism 
Binding to haem iron 
Binding to iron sulphur 
cluster 
ADP ribosylation 
Deamination 
Reacts with 
Targets 
Guanylate cyclase, 
Hemoglobin ,NADPH-
ubiquinone oxidoreductase, 
succinate-ubiquinone 
oxidoreductase 
Cis- aconitase, ribonucleotide 
reductase 
Glyceraldehyde-3- phosphate 
dehydrogenase 
DNA bases 
Superoxide; hydroxyl radical 
to form peroxynitrite 
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NO in Cardiovascular and Pulmonary Systems 
In 1980, Furchgott and Zawadski discovered that the sections of the aorta would 
relax in response to agonists only if the inner lining of endothelial cells were intact. 
However, aortic rings with no endothelial cells could not relax. Endothelial cells thus 
released an agent that relaxed vascular smooth muscle and this endothelial derived 
relaxation factor was found to be nitric oxide. 
Nitric oxide automatically regulates blood flow in response to local changes in 
some regions of the vasculature (Wennmalm et al., 1990). It interacts with smooth 
muscle, causing relaxation of the blood vessels (Yoshiki, 1995). Nitric oxide also diffuses 
into the blood stream to produce NO-haemoglobin (Iwamoto et al., 1994) or met-
haemoglobin. NOS have also been found inside platelets (Radomski et al., 1990a). It 
reduces clotting by inhibiting platelet aggregation (Radomski et al., 1990b; Pasqui et al., 
1991; Varela et al., 1992; Vallance et al., 1992 and Ivanova et al, 1993) and adhesion 
(Radomski et al., 1987a; Sneddon and Vane, 1988; de Graaf e/ al., 1992 and Siney an.d 
Lewis, 1992). The molecular basis of this mechanism includes NO activating platelet 
guanylate cyclase and adenylate cyclase (Yamakado et al., 1982; Radomski et al., 1987b; 
Gryglewski et al., 1989; Maurice and Haslam, 1990; Bowen and Haslam, 1991; Nolte et 
al., 1991), inhibiting platelet phospholipase C (Durante et al., 1992) or attaching ADP-
ribose to platelet glyceraldehyde-3-phosphate dehydrogenase (Brune et al., 1990). Sheer 
stress, an increase in blood flow through vessels, is another physical stimulus to which 
endothelial cells respond by increasing NO production (Buga et al., 1991; Kdm et 
al., 1991). A basal level of NO also regulates blood flow in the brain (Toda and 
Okamura, 1990; Tanaka et al., 1991; Faraci and Breese, 1993), heart {Chu etal., 
1990 ; Lowenstein and Snyder, 1994), lung (Fineman et al., 1991), gastrointestinal tract 
(Iwata et al., 1992) and kidney (Baumann et al., 1992; Ribeiro et al., 1992; Yukimura et 
al., 1992; Deng and Baylis, 1993). Thus NO is an endogenous auto-regulator of blood 
flow. 
NO as a Neurotransmitter 
Nitric oxide is a simple molecule with diverse biological functions. NO and 
related reactive nitrogen oxide species (RNOS) mediate intricate physiological and 
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pathophysiological effects in the central nervous system. Depending on environmental 
conditions, NO and NOS can initiate and mediate neuroprotection or neurotoxicity either 
exclusively or synergistically with other effectors (Boje, 2004). It is counter intuitive to 
consider a toxic, highly reactive gas as a crucial neurotransmitter but abundant evidence 
indicates that NO is indeed a neurotransmitter in the peripheral and central nervous 
systems. It is generated in the neuron and the glial cell of these nervous systems. 
Immunohistochemical studies have localized NOS to discrete neuronal populations, such 
as those in the myenteric plexus throughout the gastrointestinal tract (Bredt et al., 1990; 
Young et al, 1992; Grozdanovic et ah, 1994; Morgan, 2000). Neurotransmitters are 
normally stored as stable chemicals in the synaptic vesicles of nerve terminals. In 
contrast, NO does not rely on vesicle storage. NO is synthesized as needed whereupon it 
promptly diffuses in all directions into nearby neurons, by passing conventional neural 
receptors (Snyder and Bredt, 1992). The signaling action of NO is both intra- and 
intercellular (Huang et al., 1998). The radical may exhibit either a up or down regulatory 
mode in the spinal cord depending upon the types of fibers activated and the intensity of 
signal input (Callsen et al., 1999). 
NO also directly regulates the formation of ion channels or receptors. It modulates 
the potassium channel to regulate the neuronal transmission (Bolotina et al., 1994; Cohen 
etal., 1994; Miyoshi, 1994). NO also modulates intestinal reflexes by direct action on 
intestinal neurons of the enteric nervous system (Yuan et al., 1995). In the peripheral 
nervous system, the main function of NO is vasoregulation. It may also play a role in 
regulation of insulin release from pancreatic beta cells (Toda et al., 1994). The renal 
blood flow is suggested to be regulated indirectly with NO through the attenuation of 
sympathetic neuronal activity in addition to the direct action (Sakuma et al., 1992; 
Togashi et al, 1992). In presence of NO, weak input signals that might otherwise be 
unnoticed by the cell can undergo amplification and result in significant physiological 
responses (Peunova and Enikoiopov, 1993). 
In addition to NO's role in neurotransmission, it is also involved in neural 
development, neural regeneration and regulation of genetic expression (Yun et al., 1997). 
Evidence to support the hypothesis that overproduction of nitric oxide might be involved 
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in conditions such as cerebral ischemia, epilepsy and cerebral infarction is still 
controversial (Dawson et o/., 1991; Mollace et al., 1991; Nowicki etal.,1991). Microglial 
cells can express the inducible fomi of NOS (Zielasek et al.,1992) and these cells have 
been implicated in the pathogenesis of multiple sclerosis, Alzheimer's disease, 
Parkinson's disease and dementia of the acquired immunodeficiency syndrome. Nitric 
oxide appears to elicit neurotoxicity by activating poly adenosine 5'-diphosphoribose 
synthase (PARS) (Zhang et al., 1994). 
NO in the Immune System 
The role of NO in the immune system is unique because NO is nonspecific and 
damages any cell or pathogen. In contrast, antibodies or cytotoxic T lymphocytes act by 
first recognizing specific pathogens or infected cells and then destroying them 
(Lowenstein and Snyder, 1992). Immune cells, including activated macrophage, 
nucleophile, monocyte, and Kuppfer cells can release a greater amount of NO than 
endothelium or nerve cells. The major function of the NO from iNOS is cytostatic and the 
cytotoxic effects on invading microorganisms or tumor cells (Croen, 1993; Farias-Eisner 
et al., 1994). The mechanism of the cytotoxicity is in the following two categories. First 
is the inhibition of the respiration of mitochondria (Stadler et al., 1991). NO strongly 
interacts with and inhibits some enzymes in the electron transfer system, because such 
enzymes contain an iron-sulfur center in the catalytic site. Second is the direct 
modulation to the DNA synthesis to inhibit some enzymes (Garg and Hassid, 1989; 
Maragos et al., 1993). NO-releasing agents usually tend to inhibit cell proliferation and 
cell mitosis (Garg and Hassid, 1993), the expected effect is thymidine uptake. The radical 
is supposed to mediate the apoptosis of many cells (Albina et al., 1993). Although NO 
production by iNOS is essential for the defense system of an organism, it is sometimes 
related to pathological conditions, including sepsis, ischemia/reperfusion, acute 
pulmonary injury, multiple organ failure syndrome, and atherosclerosis. Septic shock is 
one of the most serious pathological conditions. It is still uncertain whether a complete 
scavenging of the NO is desirable for the improvement of the pathological condition 
(Yoshida etal., 1994). 
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Nitric Oxide, a Nuisance, at Worst a Poison 
NO is a hydrophobic gaseous molecule that is highly diffusible and is highly 
reactive. It is a paramagnetic and diatomic molecule. It is also a free radical that has one 
pair electron in a 2p-pai antibonding orbital, thus NO is extremely unstable and cannot 
maintain its original form for a very long time in a biological environment (Katayama, 
1995). NO is a key participant in many physiological pathways in the body; however, its 
reactivity gives it the potential to cause considerable damage to the cells and tissues in its 
vicinity (Bumey et al., 1997). 
The reaction of NO with transition metals to form metal nitrosyls, is involved in 
both its regulatory and cytotoxic actions. The presence of porphyrin ligands markedly 
increases the affinity of NO for iron, and haem proteins are a major target (Gordge, 
1998). The main trap for NO is oxyhemoglobin, which binds NO faster by five to six 
orders of magnitude than oxygen (Stamler et al, 1992). The reaction with haemoglobin 
produces nitrate and methaemoglobin (met-Hb) (Iwamoto et al, 1994). The basis of 
many biological actions of NO is the activation of guanylyl cyclase through binding to 
the haem prosthetic group of the enzyme (Moncada and Higgs, 1991). The enzyme 
increases the production of cGMP, modulating endothelium-dependent relaxation 
(Buga et al, 1989), platelet function (Radomski et al, 1990a,b) and nitrergic inhibitory 
transmission (Rand, 1992). Other NO-sensitive metalloproteins are NOS, cytochrome 
P450 (Bredt et al, 1991b), ferritin, ceruloplasmin, myoglobin, cyclo-oxygenase, catalase, 
ribonucleotide reductase and several components of the mitochondrial respiratory chain 
(Wink and Mitchell, 1998). These reactions have wide implications for the physiologic 
and toxic effects of NO. During sustained output of NO by inducible NOS, reaction with 
oxygen becomes significant, allowing the formation of dangerous intermediates such as 
N2O3. These can mediate oxidation and nitrosation of cysteine thiols and amino groups in 
both peptides and DNA bases, as well as nitration of tyrosine residues (Wink et al, 
1994). 
Reactions between radicals are among the fastest in nature and NO combines at 
almost diffusion limited rates with superoxide (O2' ~), peroxy (N00~) and hydroxyl 
radical (' OH). The product of NO and superoxide, peroxynitrite anion (0N00~), though 
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not itself a radical, is nevertheless a powerful oxidant and a cytotoxic mediator (Xie et 
al., 1996). 
NO at submicromolar concentration competes with oxygen for cytochrome C 
oxidase to cause reversible inhibition of respiration (Brown, 1995). It can reversibly 
inhibit enzymes containing transition metals or free radical intermediates in their catalytic 
cycle (Beckman and Koppenol, 1996). NO in micromolar concentrations reversibly 
inhibits catalase and cytochrome P450 (Wink et al, 1993a). It can also inhibit 
ribonucleotide reductase, a critical enzyme for synthesis of DNA precursors that contain 
tyrosine radical (Kwon et al, 1991; Lepoivre et al, 1992). In rat kidney, proximal 
tubules subjected to hypoxia, increased NO generation which is associated with 
membrane injury, shown by cellular release of lactic dehydrogenase (Yaqoob et al., 
1996). High output of NO generation can lead to inhibition of DNA synthesis and 
cytostasis (Gordge, 1998) and in some cases to P53 accumulation, DNA fragmentation 
and apoptosis. Cytotoxicity and DNA damage resulting from excessive production of NO 
in vivo, have the potential to trigger many diseases including various types of cancer. It is 
known that excess NO deaminates deoxyribonucleosides, deoxyribonucleotides, and 
intact DNA at physiological pH (Sugiura and Matsumoto, 1995). It also induces strand 
breaks and alkylation by nitrosamines formed by reaction of amines with nitrosating 
agents derived from NO (Ohshima and Bartsch, 1994; Tannenbaum et al., 1994; Liu and 
Hotchkiss, 1995; Wiseman and Halliwell, 1995). 
Excessive NO production and increased iNOS induction in the liver have been 
reported in chronic liver diseases (Watanabe et al., 2001). NO stimulates angiogenesis 
and mediates the effect of different angiogenic molecules. In human tiimors, NOS 
expression and activity correlate with tumor growth and aggressiveness through 
angiogenesis stimulation and regulation of angiogenic factor expression (Morbidelli et 
al., 2004). Oveiproduction of NO has also been implicated in the pathogenesis of 
SLE (Dixit and Ali., 2004) and chronic inflammatory bowel diseases. High 
concentrations of serum nitrite /nitrates and elevated urinary nitrate:creatine ratios have 
been found in patients with rheumatoid arthritis (RA), osteoarthritis (OA), and in the 
spondylarthropathies (Morgan, 2000; Sandhu er a/., 2003). Synovial fluid nitrite levels 
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are higher than those found in serum suggesting that NO may arise within the inflamed 
joint (Farrell et al, 1992; Ueki et ai, 1996). 
Nitric Oxide and Apoptosis 
Living cells eventually die from either necrosis or apoptosis. In necrotic death, cells 
passively swell, mitochondria are disrupted, the cell membrane is lysed, and cellular 
components are released into surrounding tissues causing local edema and swelling. 
The other form of cell death, apoptosis, is a process of controlled cell suicide 
whereby cells no longer needed by the body are eliminated. In apoptotic death an active 
process of cell shrinkage occurs, followed by phagocytosis preventing nearby tissue 
inflammation or damage (Nicotera et al, 1995). Controlled apoptosis is crucial to normal 
health. The process of embryonic growth and differentiation requires that surplus cells 
die and be removed. In later adult life, disrupted apoptosis allows development of 
neoplastic cells and certain autoimmune diseases. Excessive apoptosis, however, is likely 
involved in neurodegenerative diseases and in diabetes (Morgan, 2000). 
NO has been termed as the 'mediator of lethal processes' from its close association 
with apoptosis. When the NO concentration reaches critical levels, determined by cell 
type and the local environment, regulated cell death occurs ( Nicotera et al., 1995). NO 
causes oxidative stress. Mild oxidative stress leads to apoptosis whereas severe oxidative 
stress leads to excessive cellular damage and necrotic cell death. NO also affects 
mitochondria in three ways: by reversible inhibition of respiration; irreversible 
inactivation of mitochondrial enzymes; and induction of the mitochondrial permeability 
transition. It may also nitrosylate critical thiol residues on creatine kinase, disrupting ATP 
supply by mitochondria. Small decreases in ATP levels lead to apoptosis while large 
decreases rapidly cause necrosis (Murphy, 1999). NO mediated apoptosis is implicated in 
many neurodegenerative diseases, including Alzheimer's, Parkinson's and cell death in 
cerebral ischemia (Nicotera e/fl/., 1995; Pai eM/., 1998). Combining with certain 
cytokines, NO is a primary mediator of apoptotic cell death in osteoblasts (Damoulis and 
Hauschka, 1997). 
NO at sufficient levels depresses myocardial contractility and is toxic to cardiac 
monocytes (Ing et al, 1999). By causing enterocyte apoptosis, NO produces "bare areas" 
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in the intestinal epithelium which are then susceptible to bacterial invasion and a 
subsequent systemic inflammatory response (Nadler et al., 1999). The dual role of nitric 
oxide both in endothelial cell apoptosis and survival has been observed. Endothelial cells 
undergo apoptosis via the mitochondria-dependent pathway that is regulated by NO 
production. NO-regulated endothelial cell injury thus may play a role in the disruption of 
vessel endothelium and contribute to the anti-endothelial cell antibody (AECA)-induced 
pathogenesis of vasculopathy (Lin et al, 2004). 
Apoptosis is an important mechanism by which NO may contribute to the 
pathogenesis of SLE and can be implicated in SLE pathogenesis in at least three different 
ways; 
1. As antigen, apoptotic material drives autoimmune responses. 
2. As immune modulator, impaired apoptosis makes patients susceptible to 
developing autoimmunity. 
3. As effector mechanism, apoptosis participates in target organ injury. 
The relationship of apoptosis to SLE, however, cannot fit into a simple platitude such as 
"SLE is a condition of inadequate apoptosis," or "SLE is a condition of excess apoptosis." 
Rather, roles for both "too much" and "too little" apoptosis have been found. Moreover, 
"too much" and "too little" apoptosis can occur at the same time in the same SLE patient 
(Greidinger, 2001). 
Conversely, NO demonstrates a protective effect against actinomycin induced liver 
apoptosis in mice (Akahori et al., 1999). Thus, depending upon the local tissue 
environment, NO may act as either a pro- or anti- apoptotic molecule (Stefanelli et al., 
1999). 
Antioxidant Properties of Nitric Oxide 
Being a free radical, nitric oxide has both pro- and antioxidant properties (Hallman 
and Bry, 1996). NO can be protective against oxidative injury, depending on the specific 
conditions (Kanner e/a/., 1991). A nitric oxide radical can both sfimulate lipid oxidation 
and mediate oxidant-protective reactions in membranes (Radi et al., 1991). At high rates 
of NO production, the pro-oxidant versus antioxidant outcome depends critically on the 
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relative concentrations of the individual reactive species (Rubbo et al., 1994). The pro-
oxidant reactions of NO occur with superoxide, whereas the antioxidant effects of NO 
consequent to direct reactions with alkoyl and peroxyl radical intermediate during lipid 
peroxidation, terminating the propagation of lipid radical chain reactions (Rubbo et al, 
1994). 
Nitric oxide limits injury to target molecules or tissues during events associated 
with excess production of reactive oxygen species. These include inhibition of oxidative 
killing of murine lung fibroblasts and mesencephalic neurons (Wink et al., 1993b), 
attenuation of low-density lipoprotein oxidation (Graham et al., 1993; Hogg et al., 1993) 
and modulation (Kurose et al., 1994) and reduction of ischemia-reperfusion injury (Payne 
andKubes, 1993). 
Hydrogen peroxide mediates oxidation of different biological molecules that may 
result in tissue damage (Wink et al, 1993b). NO does not react directly with *0H, but is 
able to protect cells against *OH-mediated toxicity (Wink and Mitchell, 1998). NO 
induces ferritin, haem oxygenase, superoxide dismutase and endonuclease IV, which are 
protective proteins against oxidative stress, providing a cellular signal to up-regulate a 
variety of protective genes (Nunoshiba et al, 1993; Kim et al, 1995). 
Nitrate (NO3) and Nitrite (NO2") 
NO reacts with O2 to form higher oxides of nitrogen, in a relatively slow reaction in 
places where there is high concentration of O2. The essential fate of NO* is oxidation to 
(N03~) and (N02~), end products of NO metabolism that are rapidly distributed 
throughout the body and excreted in the urine. Overall, this oxidative metabolism of NO 
involves the formation of a number of intermediates in which the oxidation state of 
nitrogen ranges from +1 to +5 (N2O nitrous oxide, N2O3 dinitrogen trioxide, NO2 
nitrogen dioxide, N2O4 dinitrogen tetroxide, N2O5 dinitrogen pentoxide) and several of 
these intermediates are presumed to be actively involved in the various biological actions 
ofNO(vanderVlieteM/., 1999). 
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Peroxynitrite (ONOO^ 
Peroxynitrite is an important chemical species relative to the cytotoxic effect of NO. 
This compound, formed with NO and superoxide anion (Carreras et al., 1994) is a strong 
oxidant that damages cell membranes and proteins (Beckman et al., 1990; Koppenol et 
al., 1992 ; Matheis et al, 1992; Yu et al., 1994). 
An immune cell that could release a great amount of NO and superoxide anion 
would be a major source of peroxynitrite (Ischropoulos et al, 1992). It has been reported 
that endothelium also releases peroxynitrite through the stimulation of agonists (Kooy 
and Royall, 1994). The most serious bioactivity of the anion may be related to endothelial 
damage (Haddad et al, 1993). Loss of the barrier of endothelium is often seen in the first 
stage of various oxidative damages in the biological system. The authentic 0N00~ or 
0N00~ donor, SIN-1, clearly damages the endothelial cell (Beckman et al, 1990). The 
nerve cell is also damaged by the anion (Lipton et al, 1993; Oury et al, 1993). The 
neuronal death is caused not by the NO molecule but by peroxynitrite (Lipton et al, 
1993). Some of the 0N00~ mediated pathological conditions include Parkinson's 
disease, arteriosclerosis, Alzheimer's disease, Huntington's disease, hypertension, 
multiple sclerosis, autoimmune myocarditis and others (Kuo et al, 2000). 
Protein Nitration 
NO and its intermediates can not only cause nicks in the supercoiled plasmid DNA 
(Salgo et al, 1995) but can also oxidize a variety of biomolecules including both proteins 
and non-protein thiols (Radi et al, 1991), protein sulphides (Moreno and Pryor, 1992; 
Pryor et al, 1994), lipids (Moncada et al, 1991) and deoxyribose (Beckman et al, 
1990). 
Peroxynitrite can modify proteins through oxidation of tiyptophan and cysteine, 
formation of carbonyl moieties and cleavage of proteins (Ischiropoulos and Al-Mehdi, 
1995). One persistent footprint left by peroxynitrite is nitration of phenolic rings, 
including tyrosine residues in proteins forming 'nitrotyrosine'. It can also be formed upon 
reaction of free or protein bound tyrosine with NO2*, NOa ,^ HONO and NO2CI 
(Shigenaga e/a/., 1997). Even cigarette smoke can nitrate tyrosine (Halliwell, 1997). 
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Nitrotyrosine has been identified as a stable end product and marker of inflammation and 
NO production. The mechanism of the formation of 3-nitrotyrosine and dityrosine are 
shown in Figure 4 and 5. Nitrotyrosine serves as a long term indicator of NO-mediated 
protein modification as the measure of NO production can be falsely elevated by 
exogenous dietary and medication sources of nitrite and nitrate and reduced by serum 
thiols (Oates et al., 1999). If significant NO production occurred two weeks ago, then 
returned to baseline, the level of nitrotyrosine in serum may still be elevated due to the 
long half life of some serum proteins (Gilkeson et al, 1998). Tyrosine nitration can 
inactivate enzymes and receptors that depend on tyrosine for their activity (Ye et al, 
1996), e.g. E.coli glutamine synthase (Jiao et al, 2001), prostacyclin synthase (Zou et al, 
1997) and cytochrome P450 2B1 (Roberts et al, 1999). Nitration also prevents 
phosphorylation of tyrosine residues important for signal transduction. Nitrotyrosine 
levels have been observed in injured tissues by both immunohistochemical techniques 
and qualitative analysis with HPLC or gas chromatograpy and mass spectrometry 
(Pfeiffer et al, 2001). Protein nitration occurs in a variety of cardiac and vascular disease 
states (Mihm et al, 2000). It may also be an important contributor to organ dysfunction 
disease (Ischiropoulos and Al-Mehdi, 1995; Zou et al., 1997). 
Elevated nitrotyrosine levels have been detected in patients during renal 
failure, chronic smoking, sepsis and atherosclerotic plaques (Fukuyama et al, 1997; 
Petnizzelli et al, 1997; Leeuwenburgh et al, 1997). The levels of nitrotyrosine are also 
elevated in patients with rheumatoid arthritis and have also been observed in patients 
with celiac disease as well as SLE (Gilkeson et al, 1998; Oates et al, 1999). 
Nitrotyrosine has been detected from lung sections of patients and animals with acute 
lung injury (Haddad et al, 1994; Kooy et al, 1995), idiopathic pulmonary fibrosis (Saleh 
e/a/., 1997) and acute respiratory distress syndrome (ARDS) (Sittipunt e/a/., 2001). 
Peroxynitrite degrades surfactant by causing nitration of its tyrosine residues of surfactant 
proteins, formation of lipid peroxides and loss of surface activity (Haddad et al, 
1993). Plasma nitrotyrosine was elevated in premature infants who developed chronic 
lung disease (CLD) (Banks et al, 1998). The presence of superoxide, transient metal, 
high concentrations of NO and oxygen and the absence of thiol groups, urate and 
ascorbate in the airways promote the destructive role of NO, as the generation of 0N00~ 
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Peroxynitrite Q H 
Tyrosine 
O" OH OH 
Tyrosyl radical 
• MOa' + HgO 
' C ^ • MO," 
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Tyrosyl radical 3-Nitrotyrosine 
/T^ * frTs 
Tyrosyl radicals 3,3'-Dityrosine 
WOs** 
Fig. 4. Mechanism of reaction of ONOO" with tyrosine. Peroxynitrite (0N00~) reacts 
with tyrosine in a first-order reaction via an electron transfer mechanism to form tyrosyl 
radicals and nitrogen dioxide (NO2 ) as products (Reaction 1). Subsequent radical 
combination reactions then yield 3-nitrotyrosine and 3,3'-dityrosine as products 
(Reactions 2 and 3) (van der Vliet et ai, 1999). 
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Fig. 5. Hypothetical mechanism of 3-nitrotyrosine and dityrosine formation by 
peroxynitrite (Pfeiffer et ai, 2000). 
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is accelerated or the defence mechanisms against 0N00~ toxicity are weakened 
(Eiserich et al., 1994; Hallman and Bry, 1996). In the past six years, nitration in atleast 
eighty different diseases has been described (Reiter et al, 2000). 
Nitric Oxide Scavengers 
Overproduction of NO has been implicated in a number of diseases. There are two 
approaches to reducing NO levels: inhibition of NO synthase (NOS) or the binding and 
scavenging of NO in vivo. Aerobic organisms have potent antioxidant defenses whose 
role is to neutralize and minimize the potentially cytotoxic and genotoxic effects to 
reactive oxidants. Antioxidants are key line of defence capable of scavenging free 
radicals by preventing radical formation, intercepting radicals from further activity 
(Cotgreave et al., 1988), or participating in repair of damage caused by free radicals. 
Regulation of the antioxidant capacity includes the maintenance of adequate levels of 
antioxidant and the localization of antioxidant compounds and enzymes. Control over the 
activity of prooxidant enzymes, such as NADPH oxidase and NO synthases, is crucial. 
Synthetic antioxidants mimic biological strategies (Sies, 1993). Antioxidant defences 
may be primary or secondary. The defences that directly scavenge, H2O2 and OH are 
known as primary antioxidant defence. Secondary antioxidant defences consist of the 
repair mechanisms that act on biomolecules that have undergone oxidative damage. 
There may be enzymatic or non-enzymatic antioxidant defences. Enzymatic 
antioxidant defences include superoxide dismutase (SOD), catalasc, gluththione 
peroxidase etc, whereas ascorbic acid, uric acid, glutathione are some non-enzymatic 
antioxidants distributed in biological systems. 2-(4-carboxyphenyl)-4,4,5,5-
tetramethylimidazoine-1-oxyl 3-oxide (Carboxy-PTIO) is an efficient nitric oxide 
scavenger capable of trapping nitric oxide immediately after its synthesis. Therefore, 
carboxy-PTIO can be used as one possible treatment agent against various diseases that 
involve nitric oxide. Free nitric oxide can be inactivated by scavenger chemicals such as 
methylene blue, fuscidic acid, and carboxy-PTIO. The inhibitory effect of carboxy-PTIO 
on NO is found to be two-fold stronger than those of nitric oxide synthase inhibitors 
(Akaike et at., 1993; Wolfe and Dasta, 1995; Garcia-Pascual et al., 2000). 
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Autoimmunity 
Autoimmunity is fundamentally a continuously evolving process. The autoimmune 
responses shift, drift and diversify with time not only to other epitopes in the original 
antigen but also to other related and sometimes unrelated antigens (Singh, 2004). The 
patients who have systemic autoimmune diseases become primed to recognize 
intracellular antigens. How the autoantibodies thus produced contribute to the 
pathogenesis of the disease, and how these autoantibodies access their target proteins. 
Normally, individuals do not form potentially destructive antibodies to their own cell 
components, but only to foreign antigens. This is because the body has developed a 
tolerance to the antigens (other than immunoglobulins) normally present within self This 
state of the immune tolerance to self antigens is maintained by a complex network of T 
and B lymphocytes and their regulatory products. However, in some cases, the 
intracellular autoantigen targets of many systemic autoimmune diseases become altered 
during apoptosis in ways that may change how they are perceived by the immune system. 
High concentrations of self-antigens, or in the case of viral infection, complexes of 
foreign and self-antigens, are packaged during generation of apoptotic cells. 
The packages also may contain altered fragments of self-antigens that have 
not been encountered previously by the immune system. Under normal 
circumstances, macrophages and dendritic cells clear apoptotic cells rapidly. The normal 
consequence of that clearance is that the apoptosis-altered self-antigens are either ignored 
by the immune system or tolerance to those antigens is maintained. Defects in this 
process that cause a delay in clearance could change the appearance of apoptotic cells and 
cause them to be recognized as "foreign invaders," thereby stimulating an inflammatory 
response that, in turn, activates an immune response to self-antigens (Navratil et al., 
2004). One possible explanation for the occurrence of autoimmune response is that the 
T-cell repertoires of patients include auto reactive clones that have escaped thymic 
selection (Herold, 2004). Autoantibodies can also be produced against soluble self-
antigens, which can form immune complexes. This might lead to activation of the 
complement cascade, with the formation of the anaphylactic and chemotactic fragments, 
C3a and C5a. Histamine is then released and phagocytic activity is increased, causing an 
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inflammatory response that is destructive to tissues at the site of immune-complex 
formation. This is the usual series of events during acute episodes in SLE, when auto-
antibodies to DNA generate anti-DNA: DNA complexes with subsequent inflammation. 
There are many more ways in which an autoimmune response can cause tissue damage. 
General mechanisms of action can be classified into the following groups: 
(1) Damage by complement-fixing antibodies raised against auto-antigens. 
(2)Compromiseof cellular function when autoantibodies bind to the cell surface 
receptors, which mediate, degrade or block expression of differentiated function. 
(3) Tissue damage when autoantibodies and soluble self-antigens form immune 
complexes and initiate a destmctive inflammatory response. 
(4) Damage to cells through specific T cell responses activated to destroy self-
cellular antigens. 
Autoimmune diseases are both multigenic and multifactorial in etiology. The 
triggers for autoimmune diseases are diverse and include genetic, immunologic, 
hormonal and environmental, acting singly or in combination, in time and space 
(Brickman and Shoenfeld, 2001). At present many individual mechanisms have been 
identified, but how they interact with the immune network has not yet been elucidated. 
Autoimmunity and Genetic Factors 
Autoimmune diseases show a highly familial predisposition. Clinicians treating 
patients with autoimmune disorders have been long struck by the finding that such 
patients frequently have relatives with the same or with other autoimmune disorders 
(Shoenfeld and Isenberg, 1989). Majority of genes which have been associated with 
autoimmune diseases map within the major histocompatibility complex (MHC) of man, 
or HLA region, particularly the HLA-DR and DQ sublocus. The HLA genes fiinction as 
secondary genes to allow expression of specific autoantibody or respective disease state. 
The HLA molecules that are present on the surface of all nucleated cells and platelets are 
encoded for within the MHC on the short arm of chromosome 6 in humans. The initiation 
of an autoimmune response requires that the self reactive T cells interact with self antigen 
and HLA II antigen complex with sufficient avidity for the development of autoantibody 
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in subsequent diseases (Bias et al., 1986; Goldstein and Amett, 1987; Braun and Zachary, 
1988; Amett and Moulds, 1991; Deodhar, 1992; Colbert, 2000). 
In both animals and humans, autoimmune diseases have also been linked to non-
MHC genetic factors. Fey receptor phenotypes (Oh et al., 1999), DNAse I (Walport, 
2000) and serum amyloid protein Sap genes (Walport, 2000) as well as several apoptosis 
associated genes (Oh et al, 1999) are few of the non-MHC factors suspected of 
predisposing to autoimmune diseases. 
Autoimmunity and Immunologic Factors 
Autoantibodies may be humoral or cell mediated, or a combination of both. B cells 
contribute more than antibody production to the development of autoimmune disease, 
though possessing receptors for self antigens, e.g. thyroglobulins, DNA and IgG, they do 
not normally produce significant quantities of antibodies unless they receive T cell help. 
B cells amplify an immune response through their ftmction as antigen-presenting cells. 
Epitope spreading, or the recognition of an increasing number of antigenic determinants 
on a molecule or molecular complex, is an important mechanism in autoimmunity 
(Davidson and Diamond, 2001). This process involves B cells and T cells (Nossal, 
1994; Ashton-Rickardt and Tonegawa, 1994; Von Boehmer, 1994; Weinstein et al, 
2004). In a wide variety of autoimmune diseases, the regulatory failure results in a 
significant decrease in T-suppressor cell numbers and activity, thereby unbalancing the 
T-helper/T-suppressor cell ratio. The increased T-helper/T-suppressor cell ratio has been 
noted in a wide variety of autoimmune diseases, such as SLE, Sjogren's syndrome, PSS 
or scleroderma, rheumatoid arthritis, pernicious anemia, multiple sclerosis, immune 
complex mediated renal diseases, immunologic skin diseases and many others. 
Immunologic cross reactivity and molecular mimicry has been an important 
phenomenon in autoimmune diseases (Prinz, 2004). It has been suggested that the degree 
of sequence conservation between host and given infectious agent, heat shock proteins, 
because of molecular mimicry, may provide the link between infection and subsequent 
autoimmunity. 
27 
Autoimmunity and Hormonal Factors 
Hormones as well seem to influence the expression of certain autoimmune diseases. 
It is known that hormones of the hypothalamus, thyroid and adrenal glands affect the 
homeostasis of the lymphoid system and responses to antigens, by as yet uncharacterized 
mechanisms. SLE and RA preferentially afflict women, where as more men develop 
myasthenia gravis. The predisposing factors in these instances appear to be the sex 
hormones. It is known that testosterone is immuno-enhancing. Other hormones including 
progesterone and prolactin appear to have immunoregulatory properties. How these 
hormones contribute to the disease state has not been elucidated (VanVollenhoven and 
McGuire, 1994; Walker et ai, 1998; Ahmed and Talal, 1990; Lahita,1999). 
Autoimmunity and Environmental Factors 
Environmental factors have been implicated in autoimmune diseases including 
infectious agents, medications, chemicals, toxins, and ultraviolet light (Aharon-Maor and 
Shoenfeld, 1998; Saraux et al., 1999). Ultraviolet light is known to trigger SLE 
(McGrath, 1999). D-penecillamine, a medication formerly used to treat several immune 
diseases including RA, scleroderma and primary biliary cirrhosis has been implicated in 
the development of autoimmune diseases such as SLE and glomerulonephritis (Brik et 
ai, 1995). Malignancies are common in most autoimmune diseases than in general 
population, i.e. lymphomas are 30-40 times more common in primary Sjogren's 
syndrome (Ramos-Casals et al, 2000) and, conversely, autoimmune manifestations are a 
relatively common paraneplastic manifestation, i.e. vasculitis, sensory neuronopathy or 
autoimmune encephalomyelitis (Graus et al., 1986). 
Role of Nitric Oxide in Autoimmunity 
There has been conclusive evidence that NO can participate as a mediator of tissue 
damage in autoimmune diseases (Table 4). Nitric oxide does not participate in the 
inducing phase but in the effector phase of the autoimmune response (Cross et al., 1994). 
Macrophages and PMN cells appear to be present in autoimmune inflammatory lesions 
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TABLE 4 
Implication of Nitric Oxide in some Autoimmune Diseases 
Disease 
Experimental allergic 
encephalomyelitis (EAE) 
Experimental neuritis 
(Adoptive) 
Diabetes spontaneous 
Diabetes, induced by 
streptozotocin 
Lupus like syndrome 
Arthritis 
Rheumatoid arthritis 
Ulcerative colitis 
Species 
Mouse, Rat 
Rat 
Mouse, Rat 
Mouse 
Mouse 
(MRL-lpr/lpr) 
Mouse, Rat 
Man 
Man 
Treatment with 
NOS Inhibitor 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
No 
No 
Nitric Oxide or 
Nitrite 
Production 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
Yes 
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and can even have a major role in cell damage (Vladutiu, 1995). These cells are well 
known to produce NO once NOS is induced in these cells by cytokines. There is a release 
of cytokines in autoimmune inflammation and their role in autoimmune diseases is 
becoming more apparent. Finally, in some autoimmune diseases, immune complexes 
may play a pathogenic role and it has been reported that immune complex deposition can 
lead to NO release (Mulligan et al, 1991). Devlin et al. (1994) have reported nitric oxide 
generation as a predictive parameter of acute allograft rejection. Genetically determined 
over expression of NO plays a role in etiology of autoimmunity and may also serve as a 
barrier to transplantation (Mills et al, 1994). It appears that cytokines are very important 
for NO production in autoimmune diseases, and cytokines are present in increased 
amounts in autoimmune lesions where they are produced by inflammatory cells (Kroemer 
and Martinez, 1991). A potential source of NO is Thl lymphocytes, as has been shown 
by Taylor-Robinson et al. (1993) in experimental malaria infection. In addition to 
lymphocytes (Kirk et al, 1990), human neutrophils (Moncada, 1992) and chondrocytes 
(Blanco et al, 1995) can generate NO after induction of NOS. Another possible source of 
NO is endothelial cells, and a common early feature of the autoimmune lesion is 
endothelial cell swelling, leading to the formation of high endothelium venules (Miossec, 
1993). Infiltrating macrophages, resident endothelial cells, astrocytes (Hewett et al., 
1993) or microglial cells (Zielasek et al., 1992) in the central nervous system of animals 
with EAE may secrete NO (Lin et al, 1993). 
Autoimmune diseases can be classified into two broad but overlapping groups: 
organ specific and non-organ specific (or systemic) autoimmune diseases. Grave's 
disease, Hashimoto's thyroiditis, pernicious anemia, Addison's disease, insulin dependent 
diabetes mellitus, rheumatoid arthritis, autoimmune hemolytic anemia, autoimmune 
gastritis are a few examples of organ specific diseases. Autoantibody or cell mediated 
reactions against a specific target antigen, located in a specialized cell, tissue or organ 
occurs. In systemic autoimmune diseases, by contrast, tissue injury and inflammation 
occur in multiple sites in organs, e.g., Sjogren's syndrome, systemic sclerosis, mixed 
connective tissue disease, systemic lupus erythmetosus and antiphospholipid syndrome. 
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Systemic Lupus Erythematosus 
Systemic Lupus Erythematosus (SLE) is a complicated autoimmune disease at both 
the phenotype and genotype levels in humans and in experimental mouse models. It is 
one of the most serious rheumatic diseases. According to a 2002 government study, the 
annual number of deaths had risen from 879 to 1,406 since 1979. About a third of these 
deaths occurred in people aged 15 to 44 years, mostly women. The disease, however, is 
unpredictable and varies greatly form one individual to the next. Severity also appears to 
differ among ethnic groups and countries. In Europe and North American SLE patients 
,for example, overall five-years survival rates are between 93% and 95%, while in Asia 
or Africa they are considerably lower (60% to 70%). Other research also indicates that in 
the US African-American and Hispanic patients suffer greater organ damage than 
Caucasian patients. Genetic factors appear to have some influence on specific effects of 
SLE on organ damage among ethnic groups. The poorer outlook among minority groups 
and in underdeveloped nations appears to be primarily due to less access to good health 
care. 
There is a genetic predisposition for SLE supported by family studies, which show 
sibling risk of 5-10% and identical sibling risk of >25%, whereas the population risk is 
probably closer to O.I %. It is a prototypic autoimmune disease that afflicts 
predominantly women during their child bearing age (Nambiar, 2002). Identification of 
genetic factors that contribute to susceptibility to SLE in human and mouse is difficult 
due to several reasons including disease heterogeneity and complex interactions of 
hormonal, genetic and environmental factors (Tsao, 2003; Scofield, 2004; Santiago-
Raber et al., 2004). SLE is characterized by the production of multiple autoantibodies, 
typically antinuclear and anti-DNA antibodies (Tan, 1989; Davidson et al., 1990; 
Steinberg 1992; Harada et al, 1994; Petri, 1996). In some patients antibodies are also 
produced against platelets, lymphocytes, cellular antigens such as polysaccharides 
(Kashihara et al, 1993), phospholipids (Tiikkainen et al, 1991), cell membrane 
structures (Jacob et al., 1986a,b and c) and nucleoproteins (native nucleosome, its DNA 
component and/or its histone component), nuclear ribonucleoproteins like Sm and Mo, 
cytoplasmic ribonucleoproteins like Ro/SSA and La/SSB (Stollar, 1975, 1980, 1981; 
Gabler et al, 2003). The clinical manifestations include fever, an erythematosus 
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'butterfly rash' across the face, lesions of discoid lupus or a vasculitic rash, polyarthralgia 
and arthritis, polyserositis (especially pleurisy and pericarditis), anemia, 
thrombocytopenia, renal, neurologic and cardiac abnormalities. One of the impediments 
in understanding human systemic lupus has been its marked heterogeneity (Steinberg et 
al., 1991; Steinberg, 1992). The development of a fatal immune complex (IC)-mediated 
glomerulonephritis (GN) associated with immunological abnormalities such as 
autoantibody production makes several animal models close enough to human SLE. 
Systemic Lupus Erythematosus is characterized by the formation of a variety of 
autoantibodies and subsequent development of severe glomerulonephritis. SLE is 
characterized by the development of T cell and antibody responses against a variety of 
self antigens and inflammation in multiple organs (Malaviya et al., 1988; Mills et al, 
1994; Hahn, 1998). The disease usually begins with the involvement of a few organs and 
gradually evolves into a multisystem disorder involving the skin, joints, brain, lungs and 
kidneys. The disease is characterized by immune dysregulation, leading to high level 
autoantibody production; immune complex deposition and vasculitis (Parke and 
Rothfield, 1985). The autoantibody pattern also diversifies with time (Scofield et al., 
1996). However, not all patients with SLE develop all autoantibodies or involvement of 
all organs. Evidence suggests that the initial autoimmune response in SLE is restricted to 
a few epitopes (Singh, 2004). In SLE, the phenomenon of epitope spreading offers an 
explanation for the development of autoantibody specificities to antigens that are part of 
the same molecular complex, such as the close association of anti-Ro and anti-La 
antibodies (Weistein et al., 2004). 
The initial immunizing antigen(s) that drive the development of SLE are unknown, 
but characteristics of the immune response in SLE suggest that it is an antigen-driven 
condition. A number of phenomena have been observed after inoculation with known 
antigens that distinguish antigen-driven immune responses from other patterns of immune 
activation. These include oligoclonal expansion of antigen-specific cells, up-regulation of 
parallel B and T cell responses against the same antigen, epitope spreading to 
progressively more diversified structures on the antigen and selection for immune cells 
with higher affinity for the antigen (Greidinger, 2001). In SLE, all of these phenomena 
have been identified. Immunity in SLE is directed against self antigens not targeted in 
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normal individuals, suggesting a failure of self-tolerance (Feuerstein etai, 1999). 
Apoptosis plays a crucial role in the regulation of the immune system. Disruption in 
apoptotic pathways can prevent the deletion of autoreactive cells (Kurts et ai, 1998), and 
impair the resolution of ongoing inflammatory responses (Lee et al., 1988). Some such 
disruptions have been associated with increased risk for the development of SLE. 
Impaired apoptosis can be caused by deficiencies in endogenous pro-apoptotic mediators, 
over-expression of endogenous anti-apoptotic mediators, or by acquired factors. In 
autoimmune diseases including systemic lupus erythematosus, the immune system 
attacks various autoantigens and causes damage in target organs. Recently, it has been 
found that dead cells serve as a repertoire for autoantigens which can stimulate an 
autoimmune response in sensitive persons. The mechanisms, which lead to induction and 
progress of apoptosis, include extra-cellular stimuli, intra-cellular signals, and cleavage 
of proteins. During apoptosis, several events occur including migration of intra-cellular 
components to the cell membrane, removal of apoptotic cells by specific proteins and 
complement systems, and phagocytosis of apoptotic cells by macrophages (Marai et al., 
2003). 
Environmental triggers such as viruses have been provisionally linked to the 
development of SLE, e.g. Epstein-Barr virus and adenovirus (James e/a/., 1997), human 
T cell lymphotropic virus (Brand et A/., 1999), hormonal and chemical exposure (Cooper 
et al., 1998), support a gene-environment interaction, and one cohort-comparision study 
supports a gene-gene interaction (Mehrian et al., 1998). SLE is highly variable among 
individual patients and, to some extent, between ethnic group since certain disease 
manifestations seem to cluster within racial populations whereas others do not (Petri, 
1998). 
Deficiencies in the classical pathway of the complement system have been 
implicated in the etiology and pathogenesis of systemic lupus erythematosus for several 
decades (Liu et al., 2004). Complement has both beneficial and deleterious roles in the 
pathogenesis of systemic lupus erythematosus. On the one hand, patients with SLE 
present with decreased complement levels (CI, C2 and C4) and with complement 
deposition in inflamed tissues, suggestive of a harmful role of complement in the effector 
phase of disease. On the other hand, homozygous deficiency of any of the classical 
pathway proteins is strongly associated with the development of SLE. There are two main 
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hypotheses to explain these observations. The first invokes an important role for 
complement in the physiological waste-disposal mechanisms of dying cells and immune 
complexes. The second hypothesis is based around the role of complement in 
determining the activation thresholds of B and T lymphocytes, with the proposal that 
complement deficiency causes incomplete maintenance of peripheral tolerance 
(Manderson et al., 2004). Excessive complement activation as a result of a regulator 
component deficiency leads to tissue injury that mimics that seen in 
autoimmune disease. Complement activation occurs during tissue injury and contributes 
in a major way to the expression of pathology. It appears that natural antibodies represent 
an early culprit in tissue injury following ischemia reperfusion injury. Natural antibodies 
and probably autoantibodies present in sera of patients with systemic autoimmune disease 
bind to tissues already exposed to a damaging insult, activate complement and produce 
pathology (Tsokos and Fleming, 2004). Polymorphisms in low affinity IgG (Fey) 
receptors, which are important for the clearance of immune complexes, are also 
implicated in the pathogenesis of lupus (Salmon et al., 1996; Wu et al., 1997). 
Systemic lupus erythematosus is also characterized by B cell hyperactivity in 
association with autoantibodies, most prominently those directed to components of the 
cell nucleus. The source of the antigens that drive B cell responses in SLE is unknown, 
although recent studies suggest mechanisms by which the self-antigens become 
immunogenic and stimulate responses. In addition, autoantibody crossreactivity may 
promote induction of responses to disparate antigens, foreign and self, and enable a single 
autoantibody to cause disease by cross-reactive binding. In addition to reflecting 
increased exposure to self-antigen, autoantibody responses in SLE may result from 
abnormalities in B cell signaling and regulation by cytokines (Criscione and Pisetsky, 
2003). 
B-cell activation generally requires T-cell help. T cells have been cloned from lupus 
prone mice and these were found to stimulate the production of anti-DNA antibodies and 
renal lesions when injected. Obligatoi-y and enhanced T cell help for B cells is shown in 
SLE lymphocytes by prolonged expression and co-stimulatory interaction of the helper T 
cell surface ligand. CD40 (CD40L) with B cell receptor CD40 ( Desai et al., 1996; Koshy 
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et al, 1996). The interaction of CD40L on activated T cells with CD40 on B cells, 
induces B cell proliferation and formation of germinal centers. Within germinal centers, 
fiirther cell to cell interactions leads to B cell maturation through immunoglobulin 
isotype switching, somatic mutation, clonal expansion of high affinity B cells and 
terminal differentiation to plasma cells (Reiser and Stadecker 1996; Lindhout et a/., 1997; 
Tarlinton et al, 1998). Blockade of CD40L has been shown to delay the onset of disease 
in SLE-prone mice and to stabilize or reverse existing renal disease (Mohan et a/., 1995; 
Kalled et al., 1998). Recent studies in SLE-prone mice (NZB x NZW) Fi show that an 
anti-CD40L monoclonal antibody administered to prenephritic mice inhibits both T cell 
activation and T cell dependent B cell activation (Huang et al, 2002). 
T cell abnormalities, B cell hyperactivity and abnormal cytokine production have 
been implicated to be of pathogenic importance in SLE. SLE patients have an increased 
production as well as increased serum level of the type 2 cytokines IL-10 and IL-6. 
Serum IL-10 levels correlates with the titre of anti-dsDNA antibodies in SLE patients 
(Grondal et al., 2000). The role of these cytokines in the pathogenesis of SLE is unknown 
theoretically, IL-10 could stimulate peripheral blood mononuclear cells of SLE patients 
to produce autoantibodies, and thus be important in the excess autoantibody production 
that is characteristic of SLE (Llorente et al, 1995). High IL-10 production is reported in 
healthy relatives of SLE patients in multi case families, indicating that this tendency may 
be a genetic factor in pathogenesis (Llorente et al., 1997). 
Based on intensive research during the last decades, three main mechanisms might 
contribute to the development of SLE (Lorenz et al., 2001). 
1. Increased amounts and abnormal presentation of potential autoantigens 
including nuclear antigens. 
2. T cell dependent stimulation of B cells for the production of antinuclear 
antibodies. 
3. Anti dsDNA as well as immune complex mediated organ damages. 
Role of Oxygen Free Radicals in SLE 
Oxygen free radicals are important in both natural and acquired immunity. 
Neutrophil and macrophage phagocytosis stimulates various cellular processes including 
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the "respiratory burst" whereby increased cellular oxygen uptake results in the production 
of the potent oxidant bactericidal agents (Knight, 2000), thereby killing bacteria and 
regulating the process of acute inflammation (Halliwell, 1982). Inflammatory response is 
thus advantageous for the organism. However, abnormal over activation of phagocytes 
with consequent exacerbation of reactive oxygen metabolites production may damage 
surrounding tissues and lead to diseases such as SLE (Proctor and Reynolds, 1984; 
Southomand Powis, 1988; Halliwell and Gutteridge, 1989).//j v/vo, ROS are generated 
by oxidant enzymes, phagocytic cells, ionizing radiation, etc. Superoxide anion is 
believed to be the first radical formed, mainly by the electron transport chain when O2 
picks up the single electron (Ahsan et al, 2003). ROS are implicated in the inflammatory, 
autoimmune, connective tissue disease, systemic lupus erythematosus, particularly in 
respect of processes leading to the formation of pathogenic anti-DNA antibodies. 
Damage due to inflammatory processes is seen more often in systemic diseases than 
organ specific diseases. Accumulating evidence suggests that ROS mediate apoptotic cell 
death as intracellular ROS levels increase and cells undergo apoptosis (Gardner et al, 
1997; Lelli et al, 1998; Lieberthal et al, 1998). Recent studies show that mitochondrial 
hyperpolarization, increased ROS production and cytoplasmic alkalinization plays crucial 
roles in altered IL-10 responsiveness in SLE (Gergely, 2002). ROS generation through 
normal cellular metabolism and by exogenous stimulus is a constant problem for which 
cells have developed multiple defense mechanisms to survival. An imbalance between 
free radical generation and sequestration leads to oxidative stress (Ahsan et al, 2003). 
There is growing evidence for a role of oxidative stress in the etiology and pathogenesis 
of SLE (Evans er a/., 2000). DNA is a major target for oxidants resulting in 
increased autoantigen production, enhancement of antigenicity and altered cell functions 
(Blount et al, 1990; Ara andAli, 1992; Cooke et al, 1997). 
It has been proposed that in chronic inflammatory diseases such as RA and SLE, 
DNA-anti-DNA antibody complex(es) deposit in tissues and induce inflammation 
(Naparstek and Madaio, 1997). The phagocytic cells may then release ROS at the site of 
injury (Allan et al, 1988). These oxygen species being highly reactive may penetrate 
cellular membranes and react with nuclear DNA (Allan et al, 1987; Stollar, 1981). It has 
been reported that anti-DNA antibodies found typically in SLE have greater capacity to 
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bind to ROS-modified DNA (Blount et al, 1989). Recent studies have demonstrated that 
after modification with ROS, DNA becomes highly immunogenic and the induced 
antibodies exhibit variable binding to native DNA (Ahmad et al., 1997; Ashok et al, 
1997; Ashok and Ali, 1999). It has been postulated that ROS modified DNA is more 
discriminating antigen for the diagnosis of SLE than native DNA (Blount et al, 1990; 
1991, Ara et al, 1992; Ara and Ali, 1993). Defective DNA damage processing has been 
reported in SLE. Lymphocytes isolated from patients suffering from SLE contain 
increasing levels of 8-oxodG in DNA (Bashir et al, 1993), a marker of oxidative 
damage. An increase in serum 8-oxodG were detected in SLE patients implying a defect 
in the processing of 8-oxodG in SLE (Evans et al, 2000). 
Protein structure and thus functions are also modified by ROS. Metal ion catalyzed 
protein oxidation results in addition of carbonyl groups, cross-linking and fragmentation. 
Aldehydes of lipid peroxidation can react with sulphydryl (cysteine) or basic amino acids 
(histidine, lysine) affecting their biological characteristics. Similarly, modification of 
individual nucleotide bases, single strand breaks and cross-linking are the typical affects 
of ROS on nucleic acids (Aruoma et al, 1991). 
Recent studies from our laboratory have been carried out to synthesize and 
characterize the photoconjugates between positively charged amino acids (lysine and 
arginine) and the polydeoxyribonucleotide C [poly(dC)]. A strong recognition of 
photoadducts was observed with anti-DNA autoantibodies found in the sera of SLE 
patients. These photoadducts were found to be effective inhibitors and their relative 
affinity was substantially higher than native poly (dC). These results have pointed to the 
likelihood of modifications to polynucleotides in DNA for its better recognition by SLE 
autoantibodies as a causative agent for the induction of circulating anti-DNA or anti-
polynucleotide antibodies. Therefore, it appears that lysine and arginine have a pivotal 
role in the generation of these antibodies (Dixit et al, 2003). 
Native calf thymus DNA and poly(dA-dT).poly(dA-dT) have also been photo-
adducted with 8-methoxypsoralen inducing formation of interstrand photo-crosslinks. It 
has been found that crosslinked species of DNA-8-M0P and poly(dA-dT)-8-MOP 
photoadducts recognize previously defined monoclonal anti-Z-DNA antibody. These 
studies pointed out that conformational changes in DNA arising from the photo-
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addition might have provided neoantigens for the induction of autoantibodies to DNA 
which in turn has resulted in autoimmune disease (Arif and AH, 1996). 
It has now been estabhshed clearly that not only oxygen but also nitrogen free 
radicals play an important role in the pathogenesis of several human diseases. Reactive 
nitrogen species is produced by the reaction of nitric oxide with Oa*" or peroxide. Nitric 
oxide radical participates in some pathological conditions such as arthritis, autoimmune 
diseases, vasculitis , asthma, hypertension, etc. It is also an unstable molecule, like ROS 
but less reactive, and can react with proteins, O2 and 02*~ (Ahsan et al, 2003). 
Role of Nitric Oxide in SLE 
There is increasing evidence that nitric oxide (NO) may be important in the 
pathogenesis of systemic lupus erythematosus (SLE). Studies using N^-monomethyl-L-
arginine in MRL-lpr/lpr mice indicate that nitric oxide is important in the pathogenesis of 
glomerulnephritis, arthritis and vasculitis (Weinberg et al., 1994; Oates et al, 1997). NO 
is an importr.nt mediator of the inflammatory response. The work of Gilkeson e/o/. 
(1997), studying inflammation in MRL-lpr/lpr mice with genetically disrupted N0S2, 
highlights the heterogeneity and complexity of the role of N0S2 and nitric oxide. 
MRL-lpr/lpr mice over express N0S2 and over produce nitric oxide, parallel with the 
development of autoimmune syndrome with a variety of inflammatory manifestations. 
Previous studies have shown that nitric oxide production with nonselective NOS inhibitor 
N°-monomethyl-arginine reduced glomerulonephritis, arthritis and vasculitis. To ftirther 
define the role of nitric oxide and N0S2 in disease, mice with targeted disruption of 
N0S2 were produced by homologous recombination. Measures of nitric oxide production 
were markedly decreased in the MRL-lpr/lpr (-/-) mice (homozygous for disrupted 
N0S2), compared with MRL-lpr/lpr (+/+) (wild type), with intermediate production by 
the MRL-lpr/lpr (+/-) mice (heterozygous for dismpted N0S2). One possible explanation 
for the differences observed in NO production between SLE patients and controls is 
variation in the 5' promoter region of the N0S2 gene, which controls N0S2 transcription 
(Lopez-Nevot et al, 2003). 
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Retrospective studies have suggested a role of NO in the pathogenesis of SLE by 
demonstrating elevated levels of NO in these patients. Murine models of SLE 
demonstrate abnormally high levels of NO compared with normal mice, while systemic 
blockade of NO production reduces disease severity. Native DNA per se is a weak 
immunogen, while its modified forms have been shown to be immunogenic. Recent 
studies from our laboratory have demonstrated that after modification with ROS and NO, 
DNA became immunogenic and the induced antibodies exhibited variable binding to 
native DNA. Nitric oxide modification exposes base residues in the DNA backbone and 
the minor regions of single-stranded DNA (ssDNA), rendering it highly immunogenic 
(Dixit and Ali, 2004). Two potential sources of excessive NO are activated endothelial 
cells and keratinocytes via up regulated N0S2 (Belmont et ai, 1997). Serum 
nitrite/nitrate level, which is an index of nitric oxide production, was found to correlate 
with the disease activity and with the levels of antibodies to dsDNA. Subjects with active 
lupus nephritis had higher levels of serum nitrotyrosine than those without renal disease, 
suggesting that overproduction of NO may play a pathogenic role in SLE and lupus 
nephritis (Gilkeson et ai, 1998; Oates et al., 1999). The significance of oxidative stress 
and NO and antioxidants in SLE has also been reported (Mohan and Das, 1997). 
Eicosapentaenoic acid and docosahexaenoic acid (essential fatty acids) can modulate 
oxidative stress and nitric oxide synthesis and may have a regulatory role in the synthesis 
of antioxidant enzymes, such as superoxide dismutase and glutathione peroxidase. They 
have also suggested that measurement of lipid peroxides, nitric oxide and anti-oxidants 
can be used as markers to predict prognosis in patients with SLE. 
Role of 3-Nitrotyrosine in SLE 
A correlation between serum nhrate/nitrite (N/N) levels and serum nitrotyrosine 
levels with lupus disease activity has been observed. Serum N/N levels and serum 
nitrotyrosine levels, although both measures of NO production, may not necessarily 
correlate in individual patients at a given time. Serum N/N are direct metabolites of NO 
and are rapidly cleared from the serum. They thus reflect systemic NO production at that 
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time, similar in a way to measures of serum glucose in diabetes. Nitration of tyrosines, 
however, is irreversible and can be detected as long as the nitrated protein is in 
circulation. Serum nitrotyrosine levels reflect NO production over time, perhaps most 
analogous to serum glycosylated hemoglobin in diabetes (Gilkeson et al, 1998). 
Peroxynitrite levels (as measured by 3-nitrotyrosine) correlate more significantly 
among African-Americans with disease activity than the frequently used measure of 
serum N/N. Lupus patients with no disease activity have similar sera 3-nitrotyrosine 
levels to control, suggesting that abnormal NO production occurs in disease flares only. 
The differential expression of N/N and 3-nitrotyrosine in Caucasian and African-
American lupus subjects suggests that more oxidative stress (i.e., superoxide production) 
accompanies NO production among African-Americans with lupus. The increased 
peroxynitrite production in this group of patients may explain the more aggressive 
clinical expression of disease in African-American (Reveilli et al, 1990; Austin et 
a/.,1994, 1995;Bakire/fl/., 1994; Alarcon e?a/., 1998; Petri, 1998; Reveilli e/a/., 1998). 
Nitrated renal proteins have been demonstrated in murine lupus nephritis, which 
corresponds with increased nitrated serum proteins and abnormal N0S2 staining in the 
kidney. As 3-nitrotyrosine correlates with overall SLEDAI scores even in the absence of 
renal disease, the kidney cannot be the only source of NO production in SLE. Elevated 
N/N levels in the cerebrospinal fluid of patients with cerebral lupus and abnormal N0S2 
expression in the keratinocytes and vascular endothelium of lupus patients in general 
have been seen. Wang et al. (1991) reported increased apoptotic activity among renal 
cells adjacent to those expressing N0S2 protein. Any or all of these mechanisms may 
contribute to NO-mediated renal damage in lupus. Free 3-nitrotyrosine and serum N/N 
are cleared renally, but senmi protein 3-nitrotyrosine should be retained in those subjects 
without proteinuria. Levels of senim 3-nitrotyrosine could be falsely reduced in patients 
with severe renal protein loss. However, subjects with proteinuria have been found to 
have elevated serum 3-nitrotyrosine despite this increased protein loss. Thus, serum 3-
nitrotyrosine is best defined as a measure of protein modification by nitric oxide (Oates et 
al., 1999). 
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Objectives of the Present Study 
Nitration of tyrosine represents in vivo a mechanism, which can severely 
compromise the cell function. The detection of 3-nitrotyrosine in pathological tissues was 
suggestive of the occurrence of nitrating pathways and considered a possible diagnostic 
marker for reactive nitrogen species production in vivo. Protein nitration occurs in a 
variety of cardiac and vascular disease states. We tested the role of tyrosine nitration in 
the etiopathogenesis of systemic lupus erythematosus. The circulating human 
autoantibodies in this autoimmune disorder are polyspecific in relation to antigen binding 
characteristics. These antibodies not only recognize nucleic acid antigens but also react 
with a number of cellular proteins. Nitrogen free radicals play a significant role in health 
and disease. 
In the present study, commercially available poly L-tyrosine was exposed to nitric 
oxide generated by sodium nitrite in acidic medium. The modified product was then 
characterized by UV and fluorescence spectroscopy, DNA adduct formation, thermal 
denaturation studies, gel filtration, electrophoresis and circular dichroism spectroscopy. 
Polyclonal antibodies against native and nitric oxide modified poly L-tyrosine were 
generated in experimental animals. Both the native and modified samples induced high 
titre antibodies. However nitric oxide modified poly L-tyrosine was found to be more 
immunogenic in comparison to native poly L-tyrosine as assessed by direct binding 
ELISA. The specificity of induced antibodies was evaluated by competition ELISA, gel 
retardation assay and dot blot assay. 
In order to assess the possible role of nitric oxide modified epitopes in the etiology 
of autoimmune diseases, sera from various SLE patients were studied for their 
recognition of native and nitric oxide modified poly L-tyrosine. In the sera of SLE 
patients, 3-nitrotyrosine has also been detected by western blot analysis. Separation of 3-
nitrotyrosine was achieved by HPLC and the concentration was calculated in SLE 
patients and the serum from the experimental animals. 
^vtATBRIAL 
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MATERIALS 
Poly L-tyrosine, 3-nitrotyrosine, carboxy-PTIO, uric acid, ascorbic acid, 
desferrioximine, calf thymus DNA, nuclease SI, DNase 1 (RNase free), bovine serum 
albumin (BSA), nitrated BSA, anti-human/anti-rabbit IgG-alkaline phosphatase 
conjugates, goat anti-rabbit-horseradish peroxidase (HRP) conjugate, 4-chloro-l-napthol 
or diaminobenzidine p-nitrophenyl phosphate, ethidium bromide, Coomassie Brilliant 
Blue G-250 and R-250, sodium dodecyl sulphate, Tween-20, Triton X-100, Millipore 
filter (0,45nm pore size), Freund's complete and incomplete adjuvants, bisacrylamide 
and agarose were purchased from Sigma Chemical Company, U.S.A. Ficoll 400, xylene 
cyanole FF were purchased from Pharmacia Fine Chemicals, Sweden. 0.45 ^m Milex 
syringe filters were purchased from Millipore Inc., U.S.A. BlueRanger Prestained Protein 
Molecular Weight Marker mix was from Pierce Chemical Company, U.S.A. Folin-
Ciocalteau reagent and Blue Dextran 2000 were purchased from Centre for Biochemical 
Technology, New Delhi. Protein A-Sepharose CL-4B was from Genei, India. Absolute 
ethanol was obtained from BDH Laboratory Supplies, England. Polystyrene 
mictrotitre flat bottom ELISA plates having 96 wells (7 mm diameter) were 
purchased from NUNC, Denmark. Acrylamide, ammonium persulphate, 
N,N,N',N'tetramethylethylenediamine (TEMED) were from Biorad Laboratories Inc., 
U.S.A. EDTA (disodium salt), hydrogen peroxide, sucrose, chloroform, isoamyl alcohol, 
methanol, glacial acetic acid were from Qualigens, India. All other reagents/chemicals 
were of the highest analytical grade available. 
Equipments 
Shimadzu UV-240 spectrophotometer equipped with thermo-programmer and 
controller unit, Multiskan ELISA microplate reader, RS-232C (U.S.A.), ELICO pH meter 
model LI-120, UV-transilluminator (Vilber Lourmat, France), agarose gel 
electrophoresis assembly GNA-100 (Pharmacia, Sweden), Beckman ultracentrifuge 
Avanti 30 table top high speed refrigerated centrifuge (Beckman, U.S.A.), 
polyacrylamide gel electrophoresis assembly and western blot assembly, Trans-Blot® 
Semi Dry Transfer Cell, HPLC Biologic Duo flow were from Biorad Laboratories Inc., 
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U.S.A., RP-C18 column (Grace Vydac®, USA), Spectrophotofluorimeter (Shimadzu, 
Japan), circular dichroism spectropolarimeter (Jasco-J810) were the major equipments 
used in this study. 
Collection of Sera and Blood Samples 
Normal human sera were obtained from 10 healthy subjects and pooled. SLE sera 
were obtained from outdoor and indoor patients of the Department of Medicine, All India 
Institute of Medical Sciences, New Delhi. The SLE sera showed high titre anti-DNA 
antibodies and fulfilled the American College of Rheumatology revised criteria for the 
classification of SLE (Amett et al, 1988). 
METHODS 
Millon's Test for Tyrosine 
Phenols yield mercury derivatives when they are heated with mercuric salts. In the 
presence of nitric acid, mercury derivatives are nitrated to form brick red compound. 
Tyrosine is a phenolic amino acid found in proteins. 
Reagents 
Millons reagent: Dissolved 1 part by weight of mercury in 2 parts by weight of 
concentrated nitric acid and diluted the resulting solution with 2 volumes of water. All 
the mercury was not added at once, and the solution was kept cool during the reaction. 
Procedure 
To perform the test, a few drops of Millons reagent was added to 1.0 ml of the 
solution to be tested and boiled in a water bath. Proteins were precipitated by the strong 
acid and mercury. Proteins clumped together and those containing tyrosine turned brick 
red. 
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Determination of Protein Concentration 
Protein was estimated by the methods of Lowry et a/. (1951) and Bradford (1976). 
Protein Estimation by Folin's-phenol reagent 
(to chelate proteins) and tartarate (to keep the Cu^ ^ ions in solution at high pH) 
The protein estimation by this method utilizes alkali (to keep the pH high), Cu ions 
(a) Folin-Ciocalteau reagent 
The reagent was purchased from Centre for Biochemical Technology, New Delhi 
and diluted 1:4 with distilled water before use. 
(b) Allialine copper reagent 
The components of alkaline copper reagent were prepared as follows: 
(i) 2% sodium carbonate in 100 mM sodium hydroxide, 
(ii) 0.5% copper sulphate in 1.0 % sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) and (ii) 
in the ratio 50:1. 
(c) Procedure 
To 1.0 ml of protein sample was added 5.0 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. 1.0 ml of working Folin-Ciocalteau reagent 
was added and the tubes were read at 660 nm after 30 min. The concentration of protein 
in unknown sample was determined from the standard plot of bovine serum albumin. 
Protein Estimation by Dye Binding Metiiod 
This assay is based on colour change when Coomassie Brilliant Blue G 250 in 
acidic medium, binds strongly to protein hydrophobically and at positively charged 
groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and blue colour is observed (A.max-595 nm). 
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(a) Dye preparation 
One hundred mg Coomassie Brilliant Blue G 250 was dissolved in 50 ml of 95% 
ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting solution 
was diluted to a final volume of 1 litre and filtered through Whatman filter paper to 
remove undissolved particles. 
(b) Procedure 
To 1.0 ml of solution containing 10-100 |ig protein was added 5 ml of dye solufion 
and contents mixed by vortexing. The absorbance was read at 595 nm after 5 min against 
a reagent blank. 
Purification of Calf Thymus DNA 
Commercially obtained calf thymus DNA was purified free of proteins and single 
stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was dissolved in 0.1 X 
SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, pH 7.3) and extracted 
with an equal volume of chloroform-isoamyl alcohol (24:1) in a stoppered cylinder for 1 
hr. The aqueous layer containing DNA was separated from organic layer and re-extracted 
with chloroform-isoamyl alcohol. The DNA was precipitated with two volumes of cold 
absolute ethanol and collected on a glass rod. After drying in air, the DNA was dissolved 
in acetate buffer (30 mM sodium acetate containing 30 mM zinc chloride, pH 5.0) and 
treated with nuclease SI (150 units/mg DNA) at 37°C for 30 min to remove single 
stranded regions. The reaction was stopped by adding one-tenth volume of 200 mM 
EDTA, pH 8.0. The nuclease SI treated DNA was extracted twice with chloroform-
isoamyl alcohol mixture and finally precipitated with two volumes of cold ethanol. The 
precipitate was dissolved in phosphate-buffered saline (PBS) (10 mM sodium phosphate 
containing 150 mM sodium chloride), pH 7.4. 
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Determination of DNA Concentration 
DNA concentration was estimated colorimetrically by the method of Burton (1956) 
using diphenylamine reagent. 
(a) Crystallization of diphenylamine 
Two gram of Diphenylamine was dissolved in 200 ml of boiling hexane. After 
adding 0.5 g of activated charcoal, the hot mixture was filtered through Whatman filter 
paper and the filtrate was kept overnight at 4*^ 0 and dried at room temperature before 
use. 
(b) Preparation of diphenylamine reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial acetic acid 
and 0.75 ml concentrated sulphuric acid. The reagent was prepared fresh before use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and incubated 
at 70''C for 15 min. One hundred microlitre of 5.43 mM acetaldehyde was added 
followed by 2.0 ml of freshly prepared diphenylamine reagent. The contents were mixed 
and incubated at room temperature for 16-20 hr. Absorbance was read at 600 nm and the 
concentration of DNA in unknown samples was determined from a standard plot of calf 
thymus DNA purified free of RNA and proteins. 
Polyacryiamide Gel Electroplioresis 
PAGE for the separation of proteins was performed as described by Laemmli (1970). 
(a) Acrylamide-bisacrylamide (30:0,8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
bisacrylamide in distilled water to a final volume of 100 ml. 
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(b) Resolving gel buffer 
The stock solution was prepared by dissolving 36.3 gmTris base in 48.0 ml of 
1 N HCl. The contents were mixed, pH adjusted to 8.8 and the final volume brought to 
100 ml with distilled water. 
(c) Stacking gel buffer 
6.05 gm Tris was dissolved in 40 ml distilled water, pH titrated to 6.8 with 1 N HCl 
and the final volume adjusted to 100 ml with distilled water. 
(d) Electrode buffer 
3.03 gm Tris, 14.4 gm glycine and 1.0 gm SDS were dissolved in distilled water, 
pH adjusted to 8.3 and final volume made up to one litre. 
(e) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% agarose. The 
resolving gel mixture was prepared by mixing the components in the appropriate volume 
and poured into the space between the glass plates leaving sufficient space at the top for 
the stacking gel. After the polymerisation of separating gel, stacking gel mixture was 
poured and allowed to solidify. Protein samples containing sample dye (10% glycerol and 
0.002% bromophenol blue) were applied and electrophoresis was carried out at 60 V for 
6-8 hr. Staining of the gel was achieved with 0.1% Coomassie Brilliant Blue R 250 (in 
25% isoprpanol and 10% glacial acetic acid). Destaining was carried out in a mixture of 
10% acetic acide and 30% methanol. 
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Composition of SDS-Page Gels: 
8% Resolving Gel 
Components 
Acrylamide-bisacrylamide (ml) 
Resolving gel buffer (ml) 
Distilled water (ml) 
10%SDS(ml) 
1.5% ammonium persulphate (ml) 
TEMED (^ 1) 
Volume 
2.7 
2.5 
4.6 
0.1 
0.1 
6 
5% Stacking Gel 
Component 
Water (ml) 
30% Acrylamide (ml) 
IMTris-HCl, pH=6.8(ml) 
20% SDS (HD 
1.5% ammonium persulfate (|ll) 
TEMED (|xl) 
Volume 
3.4 
0.85 
6.25 
25 
50 
10 
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Agarose Gel Electrophoresis for DNA 
(a) Gel preparation 
1% Agarose was dissolved by heating in TAE buffer (40 mM Tris-acetate, pH 8.0 
containing 2 mM EDTA). The solution was cooled to about 45*'-50°C and then poured 
into gel tray and allowed to solidify at room temperature. 
(b) Sample preparation and loading 
Purified calf thymus DNA was mixed with one-tenth volume of sample buffer 
(0.125% bromophenol blue, 30% Ficoll 400, 500 mM EDTA in lOX electrophoresis 
buffer). The samples were loaded in the wells and electrophoresd for 2 hr at 30 mA. The 
gels were stained with ethidium bromide (0.5 |.ig/ml), viewed by illumination under UV 
light and photographed. 
Alkaline Agarose Gel Electrophoresis 
Alkaline agarose gel electrophoresis was run in buffer containing 33 mM NaOH 
and 2 mM EDTA. The NaOH and EDTA were added after the agarose had dissolved. 
The samples were prepared for loading by adding sample dye (10% glycerol and 0.002% 
bromophenol blue). Electrophoresis was run at 30 V for 4 hr in alkaline electrophoresis 
buffer (50 mM NaOH, ImM EDTA). 
Preparation of Poly L-Tyrosine Solution 
Poly L-tyrosine solution was prepared by dissolving the polymer in phosphate 
buffer saline (PBS), pH 11.0. The solutions were stored in aliquots at 4°C and were 
protected against light. 
Nitration of Poly L-Tyrosine by Nitric Oxide 
Poly L-tyrosine was nitrated by three different methods: 
1. Poly L-tyrosine was nitrated according to ter Steege et al. (1998). The pH of 0.5 
mg/ml poly L-tyrosine solution was adjusted to 3.5 with acetic acid. Sodium 
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nitrite was added to the final concentration of 100 mM and the solution was 
incubated at ST^ 'C for 24 hr. The solution changed colour from colourless to 
yellow after incubation, indicating the formation of nitrotyrosine. Subsequently 
the solution was dialyzed overnight in PBS, pH 9.0. 
2. Poly L-tyrosine (0.5 mg/ml) was nitrated with nitric oxide generated by the 
reduction of sodium nitrite and sodium dithionite. The nitration was performed at 
37°C for 3 hr in a volume of 1 ml containing 20 mM Tris-HCl buffer, pH 7.5. The 
reaction sample contained poly L-tyrosine (0.5 mg), sodium nitrite (400 mM) and 
sodium dithionite (40 mM). After incubation, extensive dialysis was performed 
with PBS, pH7.5. (Matsumoto and Sugiura, 1994; Dixit and Ali, 2001, 2004) 
3. Poly L-tyrosine (0.5 mg/ml) was nitrated with peroxynitrite. The nitration was 
carried out by incubating poly L-tyrosine in 100 mM sodium phosphate buffer, 
pH 7.4, containing ImM diethylenetriaminepentaacetic acid (DTPA), 1.0 mM 
nitric oxide releasing compound [diethylamine NONOate (DEA-NO)] and 1.0 
mM 1,4-hydroquinone at 37*^ 0 for 1 hr. The final volume of the reaction mixture 
was made up to 1.0 ml. The solution changed colour from colourless to pale 
yellow after incubation, as before. Subsequently the solution was dialyzed 
overnight in PBS (Yoshie and Ohshima, 1997). 
Spectroscopic Analysis 
The amount of protein nitrated was first determined spectrophotometrically. The 
absorbance of a series of known concentrations of nitrotyrosine at basic pH (pH > 9) was 
used as reference to determine the concentration of nitrotyrosine in the nitrated protein 
samples. 
The ultraviolet spectra of the modified and unmodified protein samples showing 
maximum nitration were recorded in the wavelength range of 230-500 nm on a Shimadzu 
UV-240 spectrophotometer. The modifications incurred on native poly L-tyrosine were 
also analysed by UV difference spectroscopy. 
Fluorescence emission and excitation spectroscopy of native and modified poly L-
tyrosine samples was also performed. 
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Circular Dichroism Measurements 
Circular Dichroism (CD) measurements of native and nitric oxide modified poly L-
tyrosine were carried out with a Jasco spectropolarimeter, model J810. The instrument 
was calibrated with d-10-camphorsulphonic acid. CD measurements of native and 
nitrated poly L-tyrosine in PBS, pH 9.0, were performed in 1 nm path length cells at a 
constant temperature of 20''C. The wavelengths chosen were from 200 nm to 300 nm. 
Scans were recorded at 20 nm per minute interval, and two spectra of each sample were 
recorded and average determined. A scan of buffer alone was recorded to adjust the 
baseline. The concentration of the protein sample used was 500 |ag/ml. Molar ellipticities 
[6] were calculated in terms of the concentration according to the following equation. 
e 
[9]= 
lO.c.l 
where, 9 is the measured ellipticity (mdeg), c is the concentration of protein sample 
(jag/ml), and 1 is the path length in cm. 
Effect of Quenchers on Modification by Nitric Oxide 
The effect of nitric oxide trapping agent (carboxy-PTIO at 10 mM), hydroxyl 
radical scavenger (D-mannitol at 10 mM), antioxidants (ascorbic acid at 10 mM and uric 
acid at 0.2 mM) and metal ion chelator (desferrioximine at 10 mM) on poly L-tyrosine 
nitration were studied by incubating the quenchers with the nitrating reaction mixture 
(Yoshie and Ohshima, 1997). 
Absorption-Temperature Scan 
Thermal denaturation analysis of poly L-tyrosine was performed in order to 
ascertain the degree of modification incurred on the protein by determining midpoint 
melting temperature (Tm). Native and modified protein sample was subjected to heat 
denaturation on a Shimadzu UV-240 spectrophotometer coupled with a temperature 
programmer and controller assembly (Hasan and Ali, 1990). All the samples were melted 
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from 20°C to 80V at a rate of 1.5"C/min after 10 min equilibration at 20"C. The change 
in absorbance at 280 nm was recorded with increasing temperature. Percent denaturation 
was calculated as follows: 
A T - A30 
Percent Denaturation = x 100 
Amax ~ A30 
Where, At = Absorbance at a temperature T^C. 
Amax = Final maximum absorbance on the completion 
of denaturation. 
A20 = Initial absorbance at 20°C. 
DNA Adduct Formation 
Fifty |.il (1 |ag/)al) solution of heat denatured DNA in phosphate buffer, pH 6.8 
(2.5mM disodium hydrogen phosphate and 5.0 mM sodium dihydrogen phosphate) was 
added to an equal volume of native and nitrated poly L-tyrosine solution (pH 11.0) of the 
same concentration. The mixture was incubated for 1 hr at 25*^ 0, dialyzed against 
phosphate buffer at 4^ *0. The difference between the native and modified poly L-tyrosine 
adduct formation with denatured DNA was visualized by PAGE (7.5 %), after staining 
with ethidium bromide (Friedman and Ts'o, 1971). 
Gel Filtration Chromatography 
The elution profile of native and modified poly L-tyrosine were studied on a 
column of Sephadex G-lOO in order to ascertain peptide bond cleavage in the modified 
protein sample in comparison to the native sample. 1 ml fractions were collected and read 
at 280 nm. 
Immunization Schedule 
Native and modified poly L-tyrosine (50 ).ig/ml) were emulsified with complete 
Frevmd's adjuvant and injected intramuscularly in female rabbits. Subsequent injections 
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were given in incomplete Freund's adjuvant. Each animal received a total of 450 |Ag of 
antigen in the course of 9 injections. Blood was collected from marginal vein of the 
ear. Serum was separated and decomplemented by heating at 56*^ 0 for 30 minutes. Pre-
immune serum was collected prior to immunization. The sera were stored in small 
aliquots at -20*^ C with 0.1% sodium azide as preservative. 
Isolation of IgG by Protein A-Agarose 
Serum IgG was isolated by affinity chromatography on Protein A-Sepharose CL-4B 
column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was applied to the 
column (12 mm X 45 mm) equilibrated with the same buffer. The wash through was 
recycled 2-3 times. Unbound proteins were removed by extensive washing with PBS, pH 
7.4. The bound IgG was eluted with 0.58% acetic acid in 0.85% sodium chloride 
(Goding, 1978) and neutralized with 1.0 ml of 1.0 M Tris-HCl, pH 8.5. Three ml 
fractions were collected and read at 251 and 278 nm. The IgG concentration was 
determined considering 1.40 OD278 = 1.0 mg IgG/ml. The isolated IgG was dialyzed 
against PBS, pH 7.4 and stored at -20°C with 0.1%) sodium azide as preservative. 
Immunological Detection of Antibodies 
Sera were tested for the presence of antibody against native and nitrated poly L-
tyrosine by enzyme linked immunosorbent assay (ELISA) and gel retardation assay. 3-
Nitrotyrosine was detected and quantitated by western blotting and high performance 
liquid chromatography (HPLC). 
(a) Western blotting 
The presence of nitrotyrosine, in the sera of SLE patients as well as immune sera 
from our immunized rabbits was detected using Western blotting (Lane and Harlow, 
1988) employing anti-nitrotyrosine antibody developed in experimental animals as probe. 
The serum was electrophoresed on 8% SDS-PAGE. The resolved proteins were 
transferred onto nitrocellulose membrane (Towbin et al, 1979), using Trans-Blot® Semi 
Dry Transfer Cell (Biorad Laboratories Inc., U.S.A). Sixteen pieces of Whatmann 
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3 mm paper and a piece of nitrocellulose membrane (NCM) of the same size as the gel 
were used. Both the gel and the NCM were pre-wet in transfer buffer (49 mM Tris; 38 
mM glycine; 0.037% SDS, 20% methanol). On the anode plate of the apparatus the 
following assembly was set up - 8 pieces of Whatmann 3 mm paper were placed followed 
by the pre-wet NCM, the pre-wet gel and finally 8 more pieces of 3 mm Whatmann filter 
paper. Current was applied at a rate of 0.8-1.2 mA/cm^ of gel for Ihr, followed by 10 V 
for 45 min. The NCM was stained with Ponceau S to verify the transfer of proteins 
from gel to membrane. Blocking was done with 4% BSA in PBS, at room temperature for 
2 hr. The blot was washed thrice with PBS-T (0.05 % Tween 20 in PBS) for 5 min each. 
It was then incubated with anti-nitrotyrosine antibody, diluted 1:150 in PBS containing 
1% BSA and kept overnight at 4°C. Blots were then washed three times for 15 min each 
in PBS-T and thereafter incubated for 1 hr at room temperature with goat anti-rabbit-
horseradish peroxidase conjugate (Sigma, U.S.A.), diluted 1:15000 in PBS containing 
1% BSA. The blots were again washed three times for 10 min each in PBS-T and once 
with plain PBS. Finally, blots were developed with 4-chloro-l-napthol or 
diaminobenzidine (Sigma, U.S.A.). 
(b) HPLC analysis 
Separation of 3-nitrotyrosine was achieved by HPLC (Biologic Duo Flow System, 
BioRad, U.S.A.) and its concentration was calculated in the sera of SLE patients as well 
as experimental animals. Sera obtained from SLE patients were diluted 1:1 (v/v) with 
eluant buffer and filtered through 0.42 i^ m Milex, disposable syringe filter before loading 
onto a C-18 reversed phase column from Vydac, U.S.A. (25 cm x 4.6 mm). The eluant 
buffer was 500 mM potassium phosphate (pH 3.0) with 10% methanol (v/v) at a flow rate 
of 0.8 ml/min. 3-Nitrotyrosine (absorbance maxima-274 nm, at pH 3.0) in various 
samples was detected at four different wavelengths (274 nm, 214 nm, 280 nm and 410 
nm) by deuterium UV-visible multiple wavelength detector. Identification of the peak 
was carried out on the basis of the retention time of standard 3-nitrotyrosine and spiking 
experiments. The absorbance of two series of known concentrations of standard 3-
nitrotyrosine at acidic pH (pH > 3.0) was used as reference to determine the 
concentration of 3-nitrotyrosine in the serum samples (Kaur and Halliwell, 1994). 
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(c) Enzyme linked immunosorbent assay 
The following reagents were prepared in distilled water and used in ELISA 
(i) Buffers and reagents 
Protein coating buffer 
15 mM Na2C03, 35 mM NaHCOj, pH 9.6 
Tris buffered saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 (used for coating DNA) 
Tris buffered saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCl, 2.68 mM KCl 
pH 7.4, containing 500 ^1 Tween 20/L. 
Carbonate-bicarbonate buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 mM 
magnesium chloride. 
Substrate 
500 i-ig p-nitrophenyl phosphate/ml of carbonate-bicarbonate buffer, pH 9.6. 
(ii) Procedure 
Antibodies were detected by ELISA using polystyrene microtitre plates as solid 
support (Ali and Alam, 2002). One hundred microlitre of 2.5 |.ig/ml antigen in protein 
coating buffer, pH 7.4 was coated in test wells of microtitre plates, incubated for 2 hr at 
37°C and subsequently overnight at 4°C. The antigen coated wells were washed three 
times with TBS-T to remove unbound antigen. Unoccupied sites were blocked with 150 
).il of 1.5% fat free milk in TBS for 4 - 5 hr at room temperature. The plates were 
washed once with TBS-T and antibody (100 |il/well) to be tested was diluted in TBS and 
added to each well. After 2 hr incubation at 37°C and overnight at 4°C, the plates were 
washed four times with TBS-T and an appropriate dilution of anti-immunoglobulin 
alkaline phosphatase 
conjugate was added to each well. After incubation at 37°C for 2 hr, the plates were 
washed four times with TBS-T and three times with distilled water and developed using 
p-nitrophenyl phosphate as substrate. The absorbance was recorded at 410 nm on an 
automatic microplate reader. Each sample was run in duplicate. The control wells were 
treated similarly but were devoid of antigen. Results were expressed as a mean of 
Aiest " Aconlrol-
(d) Competition ELISA 
The antigenic specificity of the antibodies was determined by competition ELISA 
(Hasan e/a/., 1991). Varying amount of inhibitors (0-20 |.ig/ml) were mixed with a 
constant amount of antiserum or IgG. The mixture was incubated at room temperature for 
2 hr and subsequently overnight at 4°C. The immune complex thus formed was coated in 
the wells instead of serum. The remaining steps were the same as in direct binding 
ELISA. Percent inhibition was calculated using the formula: 
Percent inhibition = 1 '^'^^^^^^^ x 100 
A 
uninhibiled 
(e) Band shift assay 
For the visual detection of antigen antibody binding and immune complex 
formation, gel retardation assay was performed (Sanford et al., 1988). A constant amount 
of antigen (native and nitrated poly L-tyrosine) was incubated with varying amounts of 
IgG in PBS, pH 7.4 for 2 hr at 37°C and subsequently overnight at 4°C. The samples 
containing 10% glycerol and 0.002% bromophenol blue were applied and electrophoresis 
was carried out at 60 V for 6-8 hr on 8% polyacrylamide gel. Staining of the gel was 
achieved with 0.1% Coomassie Brilliant Blue R 250 (in 25% isoprpanol and 10% glacial 
acetic acid). Destaining was carried out in a mixture of 10% acetic acid and 30% 
methanol. 
(f) Immunodiffusion 
Immunodiffusion was carried out by Ouchterlony double immunodiffusion method. 
Six ml of 0.4% molten agarose in PBS containing 0.1% sodium azide was poured onto 
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glass petri dishes and allowed to solidify at room temperature. Wells of 5 mm diameter 
were cut into the hardened agarose gel and an appropriate concentration of antigen and 
antibody was placed in the wells. The petri dishes were allowed to stand in a moist 
chamber at room temperature for 48-72 hr. The gels were washed with 5% sodium citrate 
for 2 hr to remove non-specific precipitin lines. The result was analysed visually. 
(g) Counterimmunoelectrophoresis 
Counterimmunoelectrophoresis was performed by the method of Kurata and Tan 
(1976) using 0.6% molten agarose in 25 mM barbital buffer, pH 8.4 conatining 0.1% 
sodium azide and poured onto 2.5 mm thick glass slides (2.5 cm X 7.5 cm) and allowed 
to harden at room temperature. The slides were stored at 4*^ C and wells of 3 mm in 
diameter were cut onto the slides at a distance of 5 mm between the two opposite wells. 
Antigen was placed in the cathodal well and antibody in the anodal well. Electrophoresis 
was performed for 30 min in 50 mM barbital buffer, pH 8.4 with a current of 3-4 Amp 
per slide. Non-specific precipitin lines were removed by treatment with 5% sodium 
citrate solution. 
(h) Dot blot assay 
Dot blot assay was essentially performed as described by Juarez et al. (1994). Five 
\i.% of each antigen was spotted separately onto nitrocellulose membrane and air-dried. 
Unoccupied sites on the membrane were blocked with 4% milk. Subsequently, the 
membrane was incubated with 1:100 diluted antibody for 2 hr at 37*^ C and overnight at 
4^C. Unbound antibody were washed with PBS-T, pH 7.4 and incubated with appropriate 
anti-IgG HRP conjugate. The reaction was developed with substrate prepared by 
adding 6 mg 4-chloro-l-napthol in 2 ml methanol, 10 ml PBS and 20 |.il H2O2. A 
control assay was simultaneously carried out without spotting antigen on membrane and 
developed in a similar manner as the test. 
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Commercially available poly L-tyrosine (PLT) was nitrated by 3 different methods 
mentioned in the previous section. The concentration of nitrated tyrosine was calculated 
spectrophotmetrically. The absorbance of a series of known concentrations of 
nitrotyrosine at basic pH (pH > 9) was used as reference to determine the concentration 
of nitrotyrosine in our nitrated protein sample. Nitric oxide generated by sodium nitrite at 
pH 3.5 gave maximum nitration when compared to the nitration by the other two methods 
(Table 5). Further studies were carried out using the sample that was nitrated by sodium 
nitrite as nitrating agent. 
The generation of nitric oxide was further confirmed by the use of its quenchers, 
i.e., ascorbate, carboxy-PTIO and uric acid. Quenching by desferrioximine (metal ion 
chelator) and mannitol (hydroxyl radical scavenger) was also studied. Decrease in percent 
nitration to the extent of 91%, 84% and 73% was seen in the case of carboxy-PTIO, uric 
acid and ascorbic acid, respectively. Mannitol and desferrioximine showed only 11% and 
25% decrease in nitration, respectively (Fig. 6). 
Spectroscopic Analysis of Native and Nitrated Poly L-Tyrosine 
UV absorption spectra studies 
The UV absorption spectra of nitrated poly L-tyrosine showed peak shift and 
hypochromicity at 280 nm. The %> hypochromicity was 25%) and peak shift was 4 nm 
towards shorter wavelength (Fig. 7). Another broad peak was observed at Xmax 420 nm, 
which is characteristic of 3-nitrotyrosine. Its absorbance maximum ranges from 350 nm 
to 450 nm, shifting from 365 nm at acidic pH (pH<3, colorless) to 420 nm at basic pH 
(pH>9, yellow). The modifications incurred on poly L-tyrosine were also analysed by 
UV-difference spectroscopy (Fig. 7, inset). The spectral curve exhibited decreased 
absorbance at around 300 nm, and an increased absorbance at around 420 nm. 
Table 5 
Percent Nitration in Poly L-Tyrosine by Nitric Oxide 
and Peroxynitrite 
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Method 
1. Nitric oxide generated by sodium 
nitrite at pH 3.5. 
2. Nitric oxide generated by the reduction 
of sodium nitrite and sodium 
dithionite. 
3. Nitrated by peroxynitrite 
Percent Nitration 
67% 
16% 
34% 
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Fig. 7. UV absorption spectra of native (—) and nitrated poly L-tyrosine (—). Inset: UV 
difference spectra of nitrated poly L-tyrosine. Native poly L-tyrosine served as control. 
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Fluorescence spectroscopy 
Fluorescence excitation and emission spectra of native and nitrated poly L-tyrosine 
showed a decrease in the fluorescence intensity (Figs. 8 and 9). Modification of the 
aromatic ring of tyrosine may attribute to the decrease in fluorescence intensity. The 
fluorescence characteristics are depicted in Table 6. 
Estimation of nitrated poly L-tyrosine by Lowry et al. method also showed decrease 
in its content, confirming the modification of the aromatic ring of tyrosine (Table 7). 
Circular dichroic spectra 
The circular dichroic spectra of the native and nitrated poly L-tyrosine showed 
substantial changes in ellipticity. Native poly L-tyrosine showed a minor but definite 
negative peak of - 2.25 mdeg at 226 nm. It also showed positive ellipticity at two 
different wavelengths. At 204.8 nm, the ellipficity was observed to be + 30 mdeg, 
whereas at 246.8 nm, an ellipticity of + 6.85 mdeg was seen. (Fig. 10). In the case of 
nitrated poly L-tyrosine, there was no ellipticity at 246.8 nm, but minor positive 
ellipticity was observed at 215 nm indicating complete loss of structure of the polymer 
by nitric oxide. 
Gel Electrophoresis Pattern of Native and Nitrated Poly L-Tyrosine 
Alkaline agarose gel electrophoresis of native and nitrated poly L-tyrosine was 
performed on 0.6% agarose gel (Fig. 11). The native sample migrated as a single band 
whereas the nitrated sample showed decrease in intensity with a broad band indicating 
formation of high and low molecular weight species. The migration of BSA was hindered 
as the electrophoresis was performed in alkaline medium. 
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Fig. 8. Fluorescence excitation spectra of native (—) and nitrated poly L-tyrosine (—). 
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Fig. 9. Fluorescence emission spectra of native (—) and nitrated poly L- tyrosine (—). 
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Table 6 
Fluorescence Characteristics of Native and Nitrated Poly L-Tyrosine 
Parameter 
Wavelength maximum 
(nm) 
Fluorescence intensity 
(arbitary units) 
Stokes shift (nm) 
Ratio of 
Quantum efficiency 
Excitation Spectra 
Nati\^ Poly 
L-Tyrosine 
278 nm 
455 
2.04 
Nitrated Poly 
L-Tyrosine 
278 nm 
222.2 
1 
Emission Spectra 
Native Poly 
L-Tyrosine 
306 nm 
438.8 
2.19 
Nitrated Poly 
L-Tyrosine 
306 nm 
200 
I 
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Table 7 
Native and Nitrated Poly L -Tyrosine Estimation by Lowry's Method 
Concentration 
20 ^g/ml 
40 fig/ml 
Native Poly L-Tyrosine 
0.066 
0.150 
Nitrated Poly L-Tyrosine 
0.011 
0.044 
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Fig. 10. Circular dichroic spectra of native (—) and nitrated poly L-tyrosine (—). 
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Fig. 11. Alkaline gel electrophoresis pattern of BSA (lane 1), native poly L- tyrosine 
(lanes 2 & 4) and nitrated poly L- tyrosine (lanes 3 & 5). Electrophoresis was 
carried out on 0.6% agarose for 4 hr at 40 mA. The gel was stained with coomassie blue. 
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Thermal Denaturation of Native and Nitrated Poly L-Tyrosine 
Thermally induced transitions were measured spectrophotmetrically at 280 nm by 
heating the samples at a rate of 1.5" C per minute. Denaturation pattern was recorded at 
temperatures from 20° C to 80° C. Increase in absorbance at 280 nm was taken as a 
measure of denaturation of the tyrosine polymer, whereas the decrease in absorbance 
showed the initiation of aggregate formation. Figure 12 shows thermal denaturation 
profile of native and nitrated poly L-tyrosine. In the case of native poly L-tyrosine, the 
aggregation occured at 48°C, i.e., till 48°C, gradual protein denaturation occurred which 
was followed by aggregation of the denatured protein molecules. While in the case of 
nitrated poly L-tyrosine, there was no aggregation as the protein structure was already 
lost. 
DNA Adduct Formation 
The interaction of native and nitrated poly L-tyrosine with denatured calf thymus 
DNA was studied. The interaction with DNA requires the tyrosine polymer to be of 
sufficient size. Smaller the polymer, lesser will be the binding. It was observed that 
denatured DNA interacted with native poly L-tyrosine more strongly than it did with 
nitrated poly L-tyrosine (Fig. 13). 
Gel Filtration Chromatography 
Native and nitrated poly L-tyrosine were nm through a column c f Sephadex G-IOO. 
Native poly L-tyrosine eluted as a single peak having polypeptides :n the range of 90 
kDa-40 kDa whereas NO modified poly L-tyrosine showed a number of peaks, ranging 
from 43 kDa-14.3 kDa (Fig. 14 a, b). The data showed peptide bond cleavage at many 
sites forming smaller polypeptides. 
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Fig. 12. Thermal denaturation profile of native and nitrated poly L-tyrosine. 
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Fig. 13. Formation of DNA adduct with native and nitrated poly L-tyrosine. Lane 1 
contained native calf thymus DNA (5 \xg), lane 2 and 3 contained DNA adduct formed 
with native poly L-tyrosine (5 \xg) (in duplicate), lane 4 and 5 contained DNA adduct 
formed with nitrated poly L-tyrosine (5 |ig) (in duplicate) and lane 6 contained DNA 
adduct formed with native calf thymus DNA and native poly L-tyrosine (5 jig). 
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Native PLT -*- NO modified PLT 
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Fig. 14. (a) Elution profile of native and nitrated poly L-tyrosine on a Sephadex G-lOO 
column, (b) Elution profile of medium range protein marker (97.4 kDa to 14.3 kDa). 
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Antigenicity of Native and Nitrated Poly L-Tyrosine 
The antigenicity of native and nitrated poly L-tyrosine was determined by inducing 
antibodies in rabbits against native and nitrated polymer. The antigenic specificity of the 
induced antibodies was assayed by direct binding, competition ELISA and dot blot assay. 
The binding of immune IgG to the respective immunogen was also probed by band shift 
assay. The antibodies raised against native and nitrated poly L-tyrosine was found to be 
non-precipitating as observed by immunodiffusion and counterimmunoelectrophoresis. 
(a) Antibodies against poly L-tyrosine 
The antiserum showed a titre of atleast 1:1600 when tested by direct binding ELISA 
(Fig. 15). Preimmune serum showed negligible binding. Induced antibodies were found 
to be specific for the immunogen. Inhibition ELISA showed a maximum of 53% 
inhibition (Fig. 16); 50% inhibition was achieved with 18.6 |ag/ml of native poly L-
tyrosine. 
(b) Antibodies against nitrated poly L-tyrosine 
Nitrated poly L-tyrosine was highly immunogenic in rabbits. The antiserum showed 
a titre of atleast 1:12800 when tested by direct binding ELISA (Fig. 17). Preimmune 
serum served as negative control, and did not show any appropriate binding to nitrated 
poly L-tyrosine. The specificity of anti-poly L-tyrosine antibodies was evaluated by 
competition ELISA. A maximum of 82% inhibition in antibody activity was obtained at 
an immunogen concentration of 20 |ig/ml. The concentration of immunogen required for 
50% inhibition was 7.9 |.ig/ml (Fig. 18). 
Purification of Immune IgG 
Immunoglobulin G (IgG) was isolated from preimmune and immune rabbit sera by 
affinity chromatography on Protein A-Sepharose CL-4B affinity column (Fig. 19). The 
purity of IgG was evaluated by SDS-PAGE in absence of a reducing a-jent. The purified 
IgG migrated as a single band upon electrophoresis (Fig. 19, inset). 
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Fig. 15. Level of induced antibodies against native poly L-tyrosine by direct binding 
ELISA with preimmune and immune sera. The microtitire plate was coated with the 
native poly L-tyrosine (2.5 |J.g/ml). 
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Fig. 16. Inhibition ELISA of immune and preimmune sera against native poly L-
tyrosine. The competitor was native poly L-tyrosine. The microtitire plate was coated 
with the native poly L-tyrosine (2.5 |ig/ml). 
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Fig. 17. Level of induced antibodies against nitrated poly L-tyrosine by direct binding 
ELISA. The microtitire plate was coated with the nitrated poly L-tyrosine (2,5 fig/ml). 
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Fig. 18. Inhibition ELISA of immune and preimmune sera against nitrated poly L-
tyrosine. The competitor was nitrated poly L-tyrosine. The microtitire plate was coated 
with the nitrated poly L-tyrosine (2.5 |ig/ml). 
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Fig. 19. (a) Elution profile of anti-poly L-tyrosine and (b) anti-nitrated poly L-tyrosine 
IgG on Protein A-Sepharose CL-4B affinity column. Inset:- SDS page of the respective 
purified IgG on 8% polyacrylamide gel. 
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Direct binding ELISA using purified IgG (against native and nitrated poly L-
tyrosine) exhibited strong binding to the respective immunogen (Figs. 20 and 21) 
whereas preimmune IgG as negative control showed negligible binding. The specificity 
of purified IgG was evaluated by competitive inhibition assay (Fig. 22) and dot blot assay 
(Fig. 23). In Figure 22, a maximum of 56% inhibition of anti-poly L-tyrosine IgG binding 
to immunogen as inhibitor was observed, whereas anti-nitrated poly L-tyrosine IgG 
showed an inhibition of 83% with the immunogen. Figure 23 shows dot blot assay of 
native and nitrated poly L-tyrosine with their respective IgG. Native and nitrated poly L-
tyrosine gave an intensive blot when bound to anti-poly L-tyrosine IgG and anti-nitrated 
poly L-tyrosine. A comparatively less intensive blot was observed in the case of BSA and 
nitrated BSA. 
Band Shift Assay 
The binding of native and nitrated poly L-tyrosine to their immune IgG was further 
ascertained by band shift assay. Constant amounts of immune IgG isolated from induced 
antibodies against native and nitrated polymer were incubated with varying amounts of 
respective immunogens for 2 hr at room temperature, and subsequently overnight at 4°C. 
The immune complex was then electrophoresed on 8% polyacrylamide gel for 4 hr at 80 
V. Figure 24(a) shows the formation of complexes between poly L-tyrosine and anti-poly 
L-tyrosine IgG with increasing concentration of immunogen. The formation of high 
molecular weight immune complexes increased as evident from the intensity of 
electrophoretic band, whereas, the amount of unbound IgG showed a proportional 
decrease in intensity. Figure 24(b) shows the formation of immune complexes between 
anti-nitrated poly L-tyrosine IgG and immunogen. There is more decrease in intensity of 
unbound IgG in proportion to the increase in immune complex formed in the case of 
nitrated poly L-tyrosine when compared to the native form. 
79 
10 20 40 60 80 
IgG CONCENTRATION (|jg/ml) 
100 150 
-•—Preimmune sera IgG —•—Native PLT immune IgG 
Fig, 20. Direct binding ELISA of affinity purified preimmune IgG, and anti-
nitrated poly L-tyrosine IgG. The microtitre plates were coated with respective antigens 
(2.5 ^g). 
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Fig. 21. Direct binding ELISA of affinity purified preimmune IgG and anti-poly 
L-tyrosine IgG. The microtitre plates were coated with respective antigens (2.5 \xg). 
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Fig. 22. Inhibition ELISA of anti-native and anti-NO-poly L-tyrosine IgG. The inhibitors 
were native and nitrated poly L-tyrosine. The microtitre plates were coated with 
respective antigen (2.5 ng/ml). 
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Fig. 23. Dot blot assay of (a) native poly L-tyrosine IgG and (b) nitrated poly L-
tyrosine IgG. Native BSA and nitrated BSA were used as control. The nitrocellulose 
membrane was coated with 5 |ag/ml of antigen. 
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Fig. 24, Band shift assay of anti-native poly L-tyrosine IgG binding to (a) native and (b) 
nitrated poly L-tyrosine. Lane 1 contained 20 jig antibody, while lanes 2-5 contained 
in addition 25|ig, 50 |ig , 75 |Xg , and 100 |lg (a) native and (b) nitrated poly L-tyrosine 
respectively. The mixture was incubated for 2 hr at37 C and subsequently overnight at 
4*'C. Electrophoresis was carried out on 8% polyacrylamide gel for 4 hr at 80 V. 
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HPLC Analysis of 3-Nitrotyrosine in Native and Nitrated Poly L-
Tyrosine Immune Sera 
Figure 25 shows representative HPLC chromatograms of standard solution of 3-
nitrotyrosine (0.005 ^M and 0.01 |AM) dissolved in the eluant buffer 500 mM potassium 
phosphate (pH 3.0). A well defined peak at retention time ~7.2 minute is observed for 3-
nitrotyrosine. 3-Nitrotyrosine was detected in the sera from the experimental animals. In 
the case of native poly L-tyrosine immune sera, (Fig. 26 a) the concentration of 3-
nitrotyrosine was negligible (0.018 [.iM) when compared to 3-nitrotyrosine present in 
the nitrated poly L-tyrosine immune sera ( 0.90 jiM) seen in Figure 26(b). 
Immunocrossreactivity of Anti-Poly L-Tyrosine 
Figures 27 to 29 show the inhibition of anti-poly L-tyrosine antibodies binding to 
native poly L-tyrosine using various inhibitors. A maximum of 53% inhibition of anti-
poly L-tyrosine antibody with immunogen as inhibitor was seen. 50% inhibition was 
achieved with around 17.8 |ig/ml of native poly L-tyrosine. Native BSA at a 
concentration of 20 |ag/ml exhibited 48% inhibiton of binding of immune IgG to native 
poly L-tyrosine. Nitrated BSA and ONOO- poly L-tyrosine showed inhibitions of 29% 
and 23%, respectively (Fig. 27). Calf thymus DNA, nitrated DNA and ROS-DNA 
showed lower inhibitions of 11 %, 9% and 6%, respectively at 20 )ag/ml inhibitor 
concentration (Fig. 28). Native nucleosomes, ROS-nucleosomes, native chromatin and 
nitrated chromatin at 20 |ag/ml showed 33%, 25%, 45% and 23% inhibition, 
respectively (Fig. 29). 
Immunocrossreactivity of Anti-Nitrated Poly L-Tyrosine 
Figures 30 to 32 show the inhibition of anti-nitrated poly L-tyrosine antibodies 
binding to nitrated poly L-tyrosine using various inhibitors. A maximum of 85% 
inhibition of anti- poly L-tyrosine antibody with immunogen as inhibitor was seen. Fifty 
percent inhibition was achieved with around 8.47 |.ig/ml of native poly L-tyrosine. Native 
BSA at a concentration of 20 ng/ml exhibited 25% inhibiton of binding of immune IgG 
to native poly L-tyrosine. NO-BSA, native poly L-tyrosine and ONOO-poly L-tyrosine 
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Fig. 25. HPLC chromatograms of standard 3-nitrotyrosine at two different 
concentrations (0.005 |j,M and 0.01 |J,M). Inset: Standard curve of 3-nitrotyrosine. 
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Fig. 26. HPLC separation of 3-nitrotyrosine from (a) native and (b) nitrated poly L-
tyrosine immune serum. Both the samples showed the presence of 3-nitrotyrosine by a 
peak at almost identical time retention to standard 3-nitrotyrosine. 
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Fig. 27. Inhibition of anti-native poly L-tyrosine IgG binding to native poly L-
tyrosine by various polymers. The competitors were native BSA, nitrated BSA, native 
poly L-tyrosine and peroxynitrite treated poly L-tyrosine. Microtitre plates were 
coated with native poly L-tyrosine (2.5 |J.g/ml). 
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Fig. 28. Inhibition of anti-native poly L-tyrosine IgG binding to native poly L-tyrosine 
by various polymers. The competitors were native DNA, nitrated-DNA and ROS-DNA. 
Microtitre plates were coated with native poly L-tyrosine (2.5 )ig/ml). 
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Fig. 29. Inhibition of anti-native poly L-tyrosine IgG binding to native poly L-tyrosine 
by various polymers. The competitors were native nucleosomes, ROS-nucleosomes, 
native chromatin and nitrated chromatin. Microtitre plates were coated with native 
poly L-tyrosine (2.5 |ig/ml). 
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showed inhibitions of 74%, 29% and 79%, respectively (Fig. 30). Calf thymus DNA, 
nitrated DNA and ROS-DNA showed lower inhibitions of 10%, 17% and 15%, 
respectively at 20 |ag/ml (Fig. 31). Native nucleosomes, ROS-nucleosomes, native 
chromatin and nitrated chromatin at 20 |.ig/ml showed 35%, 48%, 39% and 68%) 
inhibition, respectively (Fig. 32). The inhibiton data is summarized in Table 8. 
Reactivity of SLE Sera witii Native and Nitrated Poly L-Tyrosine 
Sera from twenty four patients with systemic lupus erythematosus (SLE) were 
tested for binding to native poly L-tyrosine and nitrated poly L-tyrosine. The binding 
pattern of serum antibodies to native and nitrated poly L-tyrosine was determined by 
direct binding ELISA. All the twenty four SLE sera showed stronger binding to nitrated 
poly L-tyrosine. No appreciable binding was observed with the pooled sera of normal 
subjects (Fig. 33 and 34). 
The specificity of SLE sera for native and nitrated poly L-tyrosine was evaluated by 
inhibition ELISA (Figs. 35-40). Native poly L-tyrosine showed maximum inhibition 
ranging from 19%) to 56%) in twenty four SLE sera, nitrated poly L-tyrosine showed a 
high percent inhibition ranging from 49%) to 78%). Native DNA showed higher percent 
inhibition when compared to native poly L-tyrosine ranging from 29% to 65%). The 
inhibiton data of native DNA, native and nitrated poly L-tyrosine with SLE 
autoantibodies are summarized in Table 9. 
HPLC Analysis of 3-Nitrotyrosine in SLE Patients 
Figure 61 shows a representative chromatogram of the sera pooled from ten healthy 
human subjects. No peak due to 3-nitrotyrosine was detected at the retention time 
corresponding to that of standard 3-nitrotyrosine whereas well defined peaks almost at 
retention time of standard 3-nitrotyrosine were seen for 8 SLE patients (Figs. 41-45). The 
identity of this peak was checked by adding standard 3-nitrotyrosine to SLE sera samples, 
the height of this peak increased at detector wavelength. The average concentration of 3-
nitrotyrosine in SLE patients was found to be 1.065 |.iM ± 0.556 when calculated from the 
calibration curve derived from standard 3-nitrotyrosine (Table 10). 
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-•—Native BSA 
-A- Native PLT 
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CNOO-modified PLT 
Fig. 30. Inhibition of anti-nitrated poly L-tyrosine IgG binding to nitrated poly L-
tyrosine by various polymers. The competitors were native BSA, nitrated BSA, native 
poly L-tyrosine and peroxynitrite treated poly L-tyrosine. Microtitre plates were 
coated with native poly L-tyrosine (2.5 ^g/ml). 
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Fig. 31. Inhibition of anti-nitrated poly L-tyrosine IgG binding to nitrated poly L-
tyrosine by various polymers. The competitors were native DNA, nitrated-DNA and 
ROS-DNA. Microtitre plates were coated with native poly L-tyrosine (2.5 
Hg/ml). 
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Fig. 32. Inhibition of anti-nitrated poly L-tyrosine IgG binding to nitrated poly L-
tyrosine by various polymers. The competitors were native nucleosomes, ROS-
nucleosomes, native chromatin and nitrated chromatin. Microtitre plates were coated 
with native poly L-tyrosine (2.5 ^g/ml). 
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Table 8 
Antigenic Specificity of Anti-Native and Anti-Nitrated Poly L-Tyrosine 
Antibodies 
Inhibitor 
Native BSA 
Nitrated BSA 
Native Poly L-tyrosine 
ONOO - Poly L-tyrosine 
Native DNA 
Nitrated DNA 
ROS-DNA 
Native nucleosomes 
ROS-nucleosomes 
Native Chromatin 
Nitrated Chromatin 
Maximum % inhibition at 20 |ig/ml 
Anti-poly L-tyrosine 
antibodies 
48% 
29% 
53% 
23% 
11% 
9% 
6% 
33% 
25% 
45% 
23% 
Anti-NO-poly L-tyrosine 
antibodies 
25% 
74% 
29% 
79% 
10% 
17% 
15% 
35% 
48% 
39% 
68% 
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I Native pdy L-tyrosine • Calf thymus DNA • NO-pdy L-tyrosine 
Fig. 33. Binding of 1:100 diluted SLE serum samples to native DNA, native poly L-
tyrosine and nitrated poly L-tyrosine. Pooled normal human sera (NHS) showed 
negligible binding. Microtitre plates were coated with 2.5 ^g/ml of respective antigens. 
96 
1 
0.8 
o 
5 0.6 
0.4 
0.2 
13 14 15 16 17 18 19 20 21 22 23 24 NHS 
cod 
SfflANUMBBR ^ ^ 
I Native pdy L-tynosine • Calf thymus CXMA • NQfdy L-tyrosine 
Fig. 34. Binding of 1:100 diluted SLE serum samples to native DNA, native poly L-
tyrosine and nitrated poly L-tyrosine. Pooled normal human sera (NHS) showed 
negligible binding. Microtitre plates were coated with 2.5 [ig/ml ofrespective antigens. 
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Fig. 35. Inhibition of SLE autoantibodies binding in patients 1,2, 3 and 4 by native 
DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with native 
DNA (2.5 ng/ml). 
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Fig. 36. Inhibition of SLE Autoantibodies binding in patients 5,6, 7 and 8 by native 
DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with 
native DNA (2.5 |ig/ml). 
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Fig. 37. Inhibition of SLE autoantibodies binding in patients 9, 10, 11 and 12 by 
native DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with 
native DNA (2.5 |ig/ml). 
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Fig. 38. Inhibition of SLE autoantibodies binding in patient 13, 14, 15 and 16 by 
native DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with 
native DNA (2.5 )ig/ml). 
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Fig. 39. Inhibition of SLE autoantibodies binding in patient 17, 18, 19 and 20 by 
native DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with 
native DNA (2.5 |J.g/ml). 
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Fig. 40. Inhibition of SLE autoantibodies binding in patient 21, 22, 23 and 24 by 
native DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with 
native DNA (2.5 )ig/ml). 
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Table 9 
Inhibition of SLE Autoantibodies Binding to Native DNA by Native and 
Nitrated Poly L-Tyrosine 
SLE Serum 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Mean ± SD 
Coefficient of 
variation 
Standard error 
Maximum percent inhibition at 20 i^ g/ml 
Native DNA 
43 
44 
48 
40 
50 
53 
59 
39 
55 
65 
59 
40 
39 
56 
59 
57 
54 
44 
55 
41 
44 
43 
39 
49 
48.9 ±7.95 
16.25% 
1.624 
Native PLT 
36 
32 
24 
35 
44 
22 
34 
30 
52 
54 
46 
31 
30 
30 
52 
36 
32 
56 
49 
31 
29 
20 
24 
19 
35.3 ± 11.09 
31.20% 
2.264 
NO - PLT 
54 
49 
73 
52 
49 
58 
67 
50 
69 
71 
67 
55 
60 
67 
77 . 
78 
68 
71 
65 
72 
67 
62 
64 
59 
63.5 ±8.67 
13.66% 
1.771 
Native DNA and poly L-tyrosine: t = 4.88, P < 0.001 
Native DNA and nitrated poly L-tyrosine: t = 6.05, P < 0.001 
Native and nitrated poly L-tyrosine: t = 9.79, P < 0.001 
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Fig. 41. HPLC separation of serum sample pooled from 10 healthy volunteers. The 
sample showed no peak due to 3-nitrotyrosine at almost identical time retention to 
standard 3-nitrotyrosine (the position of the expected peak is marked with an arrow). 
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Fig. 42. HPLC separation of 3-nitrotyrosine in serum sample 3 and 9 from SLE patients. 
The sample showed a peak due to 3-nitrotyrosine at almost identical time retention to 
standard 3-nitrotyrosine. 
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Fig. 43. HPLC separation of 3-nitrotyrosine in of serum sample 10 and 15 from SLE 
patients. The sample showed a peak due to 3-nitrotyrosine at almost identical time 
retention to standard 3-nitrotyrosine. 
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Fig. 44. HPLC separation of 3-nitrotyrosine in serum sample 16 and 17 from SLE 
patients. The sample showed a peak due to 3-nitrotyrosine at almost identical time 
retention to standard 3-nitrotyrosine. 
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Fig. 45. HPLC separation of 3-nitrotyrosine in serum sample 18 and 20 from SLE 
patients. The sample showed a peak due to 3-nitrotyrosine at almost identical time 
retention to standard 3-nitrotyrosine. 
Table 10 
Concentration of 3-Nitrotyrosine in SLE Patients 
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Serum Dilution 
Serum:Buffer (v/v) 
Normal sera (pooled) (1:1) 
Serum 3 (1:1) 
Serum 9 (1:1) 
Serum 10(1:1) 
Serum 15(1:1) 
Serum 16(1:1) 
Serum 17(1:10)* 
Serum 18(1:1) 
Serum 20 (1:1) 
Mean ± SD 
Standard error 
Absorbance at 
274 nm 
0.00 
0.23 
0.14 
0.07 
0.14 
0.28 
0.01 
0.06 
0.20 
Concentration of 
3-nitrotyrosine 
0.000 nM 
1.6 nM 
1.002 liM 
0.487 nM 
0.966 nM 
1.99 nM 
0.635 nM 
0.445 nM 
1.4 i^M 
1.065 ±0.556 
0.196 
* Since the amount of serum 17 was less, it was diluted to 1:10 and the result obtained 
was extrapolated to 1:1 (i.e., the concentration was multiplied by dilution factor 10). 
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Purification of Immunoglobulin G from SLE Patients 
SLE IgG was purified from SLE patients' serum 3 and 16 by affinity 
chromatography on Protein-A Sepharose CL-4B column (Fig. 46). SDS-PAGE of the 
purified IgG under non-reducing conditions showed a single homogenous band (Fig. 46, 
inset). The binding of SLE IgG to native and nitrated poly L-tyrosine was determined by 
direct binding ELISA (Figs. 47 and 48). The specificity of SLE IgG for native and 
nitrated poly L-tyrosine was also evaluated by inhibition ELISA (Figs. 49 and 50). Native 
poly L-tyrosine showed maximum inhibition of 43% and 41% with SLE IgG from serum 
3 and 16, whereas nitrated poly L-tyrosine showed a high percent inhibition of 84% and 
82% with these IgG. 
Band Shift Assay 
In order to check the working conditions of band shift assay, native and ROS 
modified plasmid DNA with SLE IgG were used. A constant amount of antigen was 
incubated with increasing amounts of SLE IgG ranging from 0-100 |.ig for 2 hr at 37'*C 
and subsequently overnight at 4°C. The immune complexes were then electrophoresed on 
1% agarose for 2 hr at 30 mA. Figure 51(a) and (b) show the binding of anti-DNA 
autoantibodies to native and ROS-plasmid DNA respectively. With increasing 
concentration of IgG there was a corresponding increase in the formation of high 
molecular weight immune complexes which resulted in retarded mobility and 
corresponding decrease in the fluorescence intensity of the unbound antigen. 
Band shift assay was then employed to visualize and confirm the interaction of 
native and nitrated poly L-tyrosine with SLE autoantibodies. A constant amount of SLE 
IgG was incubated with increasing concentration of native and nitrated poly L-tyrosine 
for 2 hr at 37°C and overnight at 4°C. These immune complexes were then 
electrophoresed on 8% polyacrylamide gel for 4 hr at 80 V. Figure 52(a) and (b) show the 
binding of SLE autoantibodies to native and nitrated poly L-tyrosine. With increasing 
concentrations of IgG there was a corresponding increase in the formation of high 
molecular weight immune complexes, which resulted in decrease in the intensity of 
unbound IgG. There was lesser immune complex formation with the native polymer 
when compared to nitrated poly L-tyrosine. 
I l l 
Fig. 46. Elution profile of SLE IgG from patient sera 3 on Protein-A Sepharose CL-4B 
affinity column. Inset:-SDS page of the purified IgG on 8% polyacrylamide gel. 
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Fig. 47. Direct binding ELISA of affinity purified human SLE IgG from patient sera 3 
to native DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with 
2.5 p-g/ml of respective antigens. 
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Fig. 48. Direct binding ELISA of affinity purified human SLE IgG from patient sera 16 
to native DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated with 
2.5 |ig/ml of respective antigens. 
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Fig. 49. Inhibition ELISA ofSLEIgG(3) binding to native DNA. The inhibitors used 
were native DNA, native and nitrated poly L-tyrosine. Microtitre plates were coated 
with native calf thymus DNA (2.5 |ag/ml). 
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Fig. 50. Inhibition ELISA ofSLEIgG(16) binding to native DNA. The inhibitors 
used were native DNA, native and nitrated poly L-tyrosine. Microtitre plates were 
coated with native calf thymus DNA (2.5 )ig/ml). 
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Table 11 
Inhibition of SLE IgG Binding to Native DNA by Native and Nitrated 
Poly L-Tyrosine 
Maximum percent inhibition at 20 |xg/ml 
SLE IgG 
3 
16 
Native DNA 
66 
61 
Poly L-tyrosine 
43 
41 
NO-poly L-tyrosine 
84 
82 
17 
Fig. 51. Band shift assay of SLE IgG (16) binding to (a) native and (b) ROS modified 
plasmid DNA. 0.5 )ag antigen was incubated with buffer (lane 1) and 25, 50, 75 and 100 \xg 
IgG through lanes 2 to 5 respectively for 2 hr at 37°C and subsequently overnight at 4°C. 
Electrophoresis was performed on 1% agarose for 2 hr at 30 mA. 
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(a) 
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Fig, 52. Band shift assay of SLE IgG (16) binding to (a) native and (b) nitrated poly L-
tyrosine. All lanes contained 20 |Xg SLE IgG, in addition lanes 2-5 contained 25|ig, 
50 |Xg , 75 ^g , and 100 fig (a) native and (b) nitrated poly L-tyrosine respectively. The 
mixture was incubated for 2 hr at 37*^ 0 and subsequently ovemi ght at 4''C. 
Electrophoresis was carried out on 8% polyacrylamide gel for 4 hr at 80 V. 
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Western Blot 
Presence of 3-nitrotyrosine was detected in 6 SLE patients by western blotting 
which demonstrated high binding to nitrated poly L-tyrosine, using anti-3-nitrotyrosine 
antibody raised in experimental rabbits (Fig. 53). Elevated levels of 3-nitrotyrosine were 
seen in the case of all the 6 patients' sera, whereas no blot was seen in the pooled normal 
human sera. An intense blot was seen in the case of nitrated BSA and nitrated immune 
serum. 
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Fig. 53. Nitrotyrosine was detected in the serum of SLE patients (3, 10, 15, 16, 18 and 20) 
by western blot analysis. Lane 1 contained protein marker (215 kDa to 18.3 kDa), lane 2 
contained nitrated BSA, lane 3 contained nitrated immune serum, lane 4 contained pooled 
normal human sera and lane 5 to 10 contained SLE sera. The blot was developed by 
anti-nitrated poly L-tyrosine IgG. The molecular weight markers are indicated. 

Humans are exposed to a whole range of nitrogen containing compounds and 
nitrosating agents, such as nitrates, nitrites, peroxynitrite, nitrogen oxides, that can react in 
vivo to form potentially carcinogenic N-nitroso compounds, as well as several carcinogenic 
C-nitro or reactive diazo compounds. Nitrosating agents can also be synthesized 
endogenously by bacteria and activated macrophages via the nitric oxide synthase (NOS) 
pathway. Endogenous nitrosation can thus occur at many locations in the body, including 
sites of chronic inflammation or infection (Bartsch and Frank, 1996; Felley-Bosco, 1998). 
Nitric oxide, a multifaceted bioregulatory agent, shows an unusual divergence of action. It 
has been demonstrated to have a direct role in cellular signaling, vasodilation and immune 
response. Macrophages also use NO as a cytotoxic agent, which may lead to DNA damage 
and protein modifications. The effects of NO at the DNA level are complex and involve 
formation of N-nitrosoamines, deamination of purines and pyrimidines, or damage induced 
by peroxynitrite. Besides inducing DNA damage, nitric oxide may also inactivate DNA 
repair/replication enzymes (Delaney and Eizirik, 1996; Luperchio et a!., 1996; Drew and 
Leeuwenburgh, 2002). 
Nitric oxide is produced within cells by the action of a group of enzymes called nitric 
oxide synthases (NOS). Presently, there are three distinct isoforms of nitric oxide synthase: 
neuronal, inducible and endothelial. While NO is a relatively unreactive radical, it is able to 
form other reactive intermediates, which could have an effect on protein function and thus on 
the functions of the entire organism. These reactive intermediates can trigger nitrosative 
damage on biomolecules, which in turn may lead to autoimmune and age related diseases due 
to structural alteration of proteins, inhibition of enzyme activity, and interferences of the 
regulatory functions (Drew and Leeuwenburgh, 2002). 
Toxicity is largely mediated via intermediates such as N2O3 and ONOO , arising from 
the reaction of NO with either molecular oxygen or reactive oxygen species. In general, such 
reactions become significant only when high concentrations of NO are generated by the 
induction of NOS (Gordge, 1998; Wink et al, 1998a and b). NO is an important mediator of 
the inflammatory response. Over expression of NOS and overproduction of NO are parallel 
with the development of an autoimmune syndrome with a variety of inflammatory 
manifestations (Gilkeson e? a/., 1997). NO is involved in a number of immunopathologies, 
including diabetes, graft-vs-host rejection, rheumatoid arthritis, SLE and multiple sclerosis 
(Cook and Cattell, 1996; Parkinson et al., 1997; Kuhn et al., 1998). 
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Protein nitration has been suggested to be a final product of the production of highly 
reactive nitrogen oxide intermediates (e.g. ONOO ) formed in reactions between NO and 
oxygen derived species such as superoxide (Gunther et ai, 2002). The most frequently 
studied marker of oxidative damage to proteins is protein carbonyl groups, oxidation of 
tryptophan, tyrosine and cysteine residue and protein fragmentation. 3-Nitrotyrosine is 
thought to be a relatively specific marker of oxidative damage mediated by ONOO . The 
biological significance of tyrosine nitration is a subject of great interest, because ampl^ 
evidence supports the formation of 3-nitrotyrosine in vivo in diverse pathological conditions. 
In addition, tyrosine nitration causes inactivation of several enzymes, influences tyrosine 
phosphorylation-mediated signal transduction, and induces apoptosis through impairment of 
microtubule formation in cells. A recent intriguing finding shows the presence of 3-
nitrotyrosine denitrase activity, which repairs protein nitration in rat tissues, suggesting that a 
tyrosine nitration-denitration pathway participates in NO or ONOO -dependent signal 
tranduction, similar to phosphorylation-dephosphorylation systems. These findings indicate 
that 3-nitrotyrosine formation has great importance not only as biomarker of nitrogen-
mediated tissue injury but also as a means to gain insight into molecular mechanisms of NO-
related physiological and pathophysiological phenomena (Sawa et ai, 2000). 
Systemic lupus erythematosus is a prototype autoimmune, multisystem and 
multifactorial disease characterized by the presence of autoantibodies to a variety of nuclear 
antigens such as DNA and histones, as well as protein antigens and protein-nucleic acid 
complexes. The marked heterogeneity of SLE autoantibodies has been one of the 
impediments in understanding the disease. SLE is also characterized by abnormal 
lymphocyte function that may be responsible for many of the clinical manifestations that are 
important in disease diagnosis (Ahsan et al, 2003; Dixit and Ali, 2004; Waris and Alam, 
2004). The role of apoptosis in the pathogenesis of SLE has been suspected. One of the 
inducers of apoptosis is the Fas (receptor/ligand) system. Nitric oxide plays a vital role in 
immunity. Apoptosis is an important mechanism by which NO may contribute to the 
pathogenesis of SLE. Elevated NO production has been suggested in the pathogenesis of 
lupus-like syndrome in MRL-lpr/lpr mice. NO concentration in exhaled air significantly 
increased in patients with SLE compared to healthy controls (Rolla et al, 1997). 
Since nitrates and nitrites are only indicators for enhanced NO production, protein 
associated nitrotyrosine might be a more suitable marker for damage induced by reactive 
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nitrogen intermediates. Furthermore, most proteins have a longer life in circulation than 
those of nitrates and nitrites. The presence of nitrotyrosine has been detected in various 
inflammatory processes (celiac disease, chronic renal failure, septic shock and atherosclerotic 
placques) and rheumatic diseases including systemic lupus erythematosus, Sjoegren's 
syndrome, vasculitis, and rheumatoid arthritis. 
In the present study, an aqueous solution of commercially available poly L-tyrosine was 
exposed to nitric oxide generated by sodium nitrite in acidic medium. The production of 
nitric oxide radical was confirmed by the use of quenchers i.e., ascorbate, carboxy-PTIO, uric 
acid, desferrioximine and mannitol. Nearly complete inhibition in the production of NO was 
observed in the presence of carboxy-PTIO, and above 70% in the case of ascorbate and uric 
acid. However, very low inhibition in the production of NO was observed when mannitol and 
desferrioximine were used. 
The UV absorption spectra of native poly L-tyrosine showed only one peak at 280 nm, 
whereas there were two peaks observed in the case of nitrated poly L-tyrosine. Peak at 280 
nm showed hypochromicity of 25% and a peak shift of 4 nm towards shorter wavelength. 
The observed change could be attributed to structural alterations as well as damage of 
chromophoric groups. Another peak was observed at wavelength of 420 nm, which is 
characteristic of 3-nitrotyrosine at pH >9. Nitration of tyrosine residues in purified proteins is 
relatively easy to detect by visible spectroscopy owing to the characteristic yellow colour, 
which was observed in this case. The UV difference spectra exhibited decrease in absorbance 
at 300 nm, and an increase in absorbance at around 420 nm. These are indicative of an 
appreciable portion of NO induced damage of the aromatic ring of tyrosine, as well as 
nitration of tyrosine forming 3-nitrotyrosine. 
Disruption of the chromophoric group of tyrosine was confirmed by fluorescence 
spectra when nitrated poly L-tyrosine showed a decrease in fluorescence intensity at both 
excitation and emission wavelengths. This was further confirmed when tyrosine was 
estimated by Lowry's method. The data showed a decrease in absorbance for nitrated poly L-
tyrosine when compared to native poly L-tyrosine. 
The right-handed a-helix stnicaire observed for native poly L-tyrosine seems to be 
completely lost in the case of nitrated poly L-tyrosine, as observed in the circular dichroij 
spectra. 
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Formation of high molecular weight species indicating aggregation of nitrated poly L-
tyrosine was seen in the alkaline agarose gel electrophoresis. Low molecular weight species 
were also observed in the case of nitrated poly L-tyrosine which indicated peptide bond 
cleavage, whereas native poly L-tyrosine showed a single band. The formation of low 
molecular weight species was confirmed by gel filtration chromatography. In the case of 
nitrated poly L-tyrosine, a number of peaks ranging from 43 kDa to 14.3 kDa were observed, 
whereas for native poly L-tyrosine, only one peak was seen in the range of 90 kDa to 40 kDa. 
Another experiment confirmed the fact that NO had caused peptide bond cleavage. The 
interaction of poly L-tyrosine with denatured DNA was studied. It has been reported that the 
interaction between the two species is non-electrostatic in nature and highly specific in 
respect of DNA bases (Friedman and Ts'o, 1971). Tyrosine is found to bind more strongly 
with purines than with pyrimidines. The interaction is dependent on the conformation of the 
nucleic acid, i.e., poly L-tyrosine can fomi insoluble complexes with denatured DNA but not 
with native DNA. The interaction also requires the polymer of tyrosine to have a sufficient 
size, smaller the polymer, lesser will be the binding. 
The thermal denaturation profile of native poly L-tyrosine showed gradual protein 
denaturation till 48^C after which protein aggregation occurred. While in the case of nitrated 
poly L-tyrosine, there was no aggregation point indicating that all the protein structure was 
already lost. This could be attributed to the disruption and structural alteration of the polymer 
on exposure to nitric oxide. 
Tyrosine is a non-essential amino acid that is synthesized in vivo from phenylalanine. 
As a building block for several important brain chemicals, tyrosine is needed to synthesize 
epinephrine, norepinephrine, serotonin and dopamine. It also aids in the proper functioning 
of organs in the body responsible for making and regulating hormones including that of 
adrenal, thyroid and pituitary glands. Tyrosine also has anti-aging benefits as it works as a 
mild antioxidant. Tyrosine in itself may not be immunogenic but its homopolymeric form 
may be immunogenic, being a large polypeptide having a right handed a-helix structure. 
Both free and protein bound 3-nitrotyrosine dramatically increased in pathologic 
conditions associated with the production of reactive oxygen and nitrogen species. There is 
mounting evidence that nitration of tyrosine residues in proteins can profoundly alter protein 
function, suggesting that protein nitration may be fundamentally related to, and be predictive 
of oxidative cell injury. At the very least, the presence of 3-nitrotyrosine in biological 
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samples indicate that reactive nitric oxide derived species were produced /// vivo, although 
the exact nature of these species remains to be determined (Crow, 1999). 
3-Nitrotyrosine immunoreactivity has been reported in several human pathological 
conditions mentioned before. In addition, numerous other disease states using non-human 
models have been shown to involve 3-nitrotyrosine formation (Crow, 1999). 
We raised polyclonal antibodies against native and nitrated poly L-tyrosine and both 
were found to be immunogenic in rabbits as revealed by the result of direct binding and 
inhibition ELISA. However nitrated poly L-tyrosine was found to be more immunogenic as 
compared to the un-nitrated form. Band shift assays and dot blot assay clearly demonstrated 
the absolute specificity of the purified immune IgG towards their respective immunogen. 
Antigenic specificity of purified IgG was confirmed by inhibition ELISA. A maximum of 
56% inhibition of anti-native poly L-tyrosine antibody with immunogen as inhibitor was 
observed at 20 ^g/ml and 50 % inhibition was achieved at 17.8 ng/ml. A maximum of 83% 
inhibition in the binding of anti-nitrated poly L-tyrosine antibody with immunogen as 
inhibitor was observed at 20 ^g/ml and, 50%) inhibition was achieved at 8.1 ^ig/ml. The data 
shows that although native poly L-tyrosine was found to be immunogenic in experimental 
animals, nitrated poly L-tyrosine was found to be more immunogenic in comparision to 
native polymer. These results suggest that the nitration of tyrosine results in the generation of 
neo-epitopes, making it a potential immunogen. 
Western blot analysis of serum from experimental animals immunized with NO-poly L-
tyrosine revealed anti-3-nitrotyrosine antibody binding to 3-nitrotyrosine in serum proteins, 
indicating the presence of 3-nitrotyrosine in immunized animals. HPLC separation and 
quantitation of 3-nitrotyrosine was also carried out for the immune sera. The serum from the 
animals immunized by native poly L-tyrosine showed negligible 3-nitrotyrosine level when 
compared to 3-nitrotyrosine present in the nitrated poly L-tyrosine immune serum. This 
could be correlated to a feature in SLE wherein nitrated free or protein bound tyrosine 
(neoantigen) play a major role in the production of SLE autoantibodies. 
Autoantibodies targeted against intracellular proteins and nucleic acids are the 
serological hallmark of the systemic rheumatic diseases, such as systemic lupus 
erythematosus (SLE), progressive systemic sclerosis (PSS), Sjogren's syndrome (SS), mixed 
connective tissue disease (MCTD) and polymyositis (PM). Each one of these diseases is 
identified by the unique autoantibodies. Antibodies to dsDNA sei-ve as an immunochemical 
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marker for the diagnosis of SLE. It has been shown that DNA after exposure to ROS presents 
a more discriminating antigen for the binding of SLE autoantibodies (Blount et al, 
1989; 1990; Ara and Mi, 1992; 1993; Cooke et al. 1997). 
Several retrospective studies have indicated a correlation between senmi nitrate/nitrite 
level and disease activity. It has also been found that serum 3-nitrotyrosine level is elevated 
among patients with SLE. In the present study, the possible role of native and nitrated poly 
L-tyrosine in SLE was probed. Autoantibodies in twenty-four different SLE sera were 
screened by direct binding and inhibition ELISA. All sera showed stronger binding to 
nitrated poly L-tyrosine when compared to native poly L-tyrosine and nDNA. No detectable 
antibody activity was found in the pooled normal human sera. 
Competition ELISA results showed 39% to 65% inhibition in the SLE autoantibodies 
binding to native DNA, whereas 19% to 56% was observed with native poly L-tyrosine as 
inhibitor. Similarly 49% to 78% inhibition was observed with NO-poly L-tyrosine as 
inhibitor. These results indicate that the nitrated poly L-tyrosine is an effective inhibitor of 
nDNA-anti-nDNA antibody interaction showing substantial difference in the recognition 
over native poly L-tyrosine as well as nDNA. Band shift assay and inhibition ELISA using 
IgG isolated from SLE serum (3 and 16) further substantiated the binding of native and 
nitrated poly L-tyrosine with SLE autoantibodies. Results of these experiments demonstrated 
that nitration of tyrosine resulted in the formation of neoantigen(s) thus inducing explicit 
immune response as compared to native polymer. The body's immunosurveillance may 
prove ineffective if the generation of nitric oxide is enhanced tremendously, as seen in 
chronic inflammation and in injured tissues. Once nitric oxide levels increase, the damage 
and nitration would be inevitable and the immunoregulatory network would be activated to 
deal with this alien nitration and modification. The subsequent production of autoantibodies 
would be a natural step. 
SLE sera were analyzed for the presence of 3-nitrotyrosine by Western blot revealing 
anti-3-nitrotyrosine antibody binding to serum proteins, suggesting that nitration of tyrosine 
moieties by nitric oxide affected some, if not all, tyrosine containing serum proteins. No blot 
was seen in the case of pooled normal human sera. 
The separation and measurement of the concentration of 3-nitrotyrosine in SLE sera 
was carried out by HPLC. Eight senmi samples showing high inhibition of DNA-anti-DNA 
antibody by NO-poly L-tyrosine were chosen. The concentration of 3-nitrotyrosine in these 
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samples was found to be 1.065 ).iM ± 0.556. Serum collected from healthy volunteers showed 
no detectable levels of 3-nitrotyrosine indicating that serum 3-nitrotyrosine level is elevated 
among patients with SLE. Serum 3-nitrotyrosine correlates directly with disease activity in 
the patients. When compared with dsDNA, and native poly L-tyrosine, 3-nitrotyrosine level 
correlated better with SLE subjects. This data confirms the overproduction of NO in human 
SLE and points out serum 3-nitrotyrosine as a new diagnostic tool for studying the role of 
nitric oxide in SLE and other diseases where production of NO is prevalant. Measurement of 
3-nitrotyrosine may be a useful probe in demonstrating NO-mediated pathology and testing 
the effectiveness of therapeutic aids in preventing damage by reactive nitrogen species. 
Based on the above studies, the following conclusions can be drawn: 
1. Poly L-tyrosine exposed to sodium nitrite at pH 3.5 resulted in the generation of nitric 
oxide, which resulted in the formation of 3-nitrotyrosine, structural alterations and 
peptide bond cleavage. 
2. 3-Nitrotyrosine was highly immunogenic in experimental animals when compared to 
native poly L-tyrosine. 
3. High level of 3-nitrotyrosine was detected in nitrated poly L-tyrosine immune serum 
when compared to native poly L-tyrosine immune serum. 
4. Induced antibodies were highly specific for respective immunogens. 
5. SLE autoantibodies showed preferential binding to nitrated poly L-tyrosine over native 
poly L-tyrosine and nDNA. 
6. Elevated level of 3-nitrotyrosine was seen in the sera of SLE patients when compared 
to healthy subjects. 
7. 3-nitrotyrosine presents a discriminating antigen for the binding of SLE autoantibodies. 
8. Nitrated tyrosine presents unique epitopes, which may be one of the factors in antigen-
driven autoimmune response in systemic lupus erythematosus. 
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